Methods and control compositions for a quantitative polymerase chain reaction

ABSTRACT

The invention relates to control compositions for a quantitative polymerase chain reaction. More particularly, the invention relates to control compositions for a quantitative polymerase chain reaction having at least one barcode sequence fragment and at least a first and a second primer binding site fragment, and to methods of their use.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. Ser. No. 16/714,125, filed Dec. 13, 2019, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Ser. No. 62/779,200 filed on Dec. 13, 2018, the entire disclosure of which is incorporated herein by reference.

INCORPORATION BY REFERENCES OF MATERIAL SUBMITTED ELECTRONICALLY

Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: 3,779 kilobytes xml file named “920006-304270.xml”, created on Aug. 8, 2022.

FIELD OF THE DISCLOSURE

The invention relates to control compositions for a quantitative polymerase chain reaction. More particularly, the invention relates to control compositions for a quantitative polymerase chain reaction having at least one barcode sequence fragment and at least a first and a second primer binding site fragment, and to methods of their use.

BACKGROUND AND SUMMARY OF THE INVENTION

The quantitative polymerase chain reaction (qPCR), which is also referred to as q-RT-PCR (i.e., quantitative real-time polymerase chain reaction), suffers from a lack of spike-in controls that can be used in every step of analysis from DNA extraction to DNA amplification. Sample swapping or sample-to-sample contamination can occur during any of these steps, but without a priori knowledge of what is in the sample, it may not be known if the samples were contaminated or swapped or contained similar genetic profiles. qPCR is used for clinical diagnosis of infectious diseases, cancer, and other genetic disorders. If a sample contaminates a neighboring sample, or sample swapping occurs, during sample processing or qPCR a healthy person could be diagnosed as having an infection or another disorder. Thus, methods and compositions to ensure that sample swapping or sample-to-sample contamination has not occurred during sample processing or qPCR are important.

Applicant has invented barcoded DNA molecules that are optionally encapsulated in a simulated cell membrane for use in qPCR. The barcoded molecule is flanked, directly or indirectly, with specific primer binding site fragments so that the barcode is amplified during a qPCR protocol. In one embodiment, a unique Taqman™ probe can be designed to correspond with each barcode to enable detection and differentiation of barcodes during qPCR. The probe can bind to the barcode to detect the barcode, presenting a unique signal to the qPCR device that can be differentiated from the signal produced by the qPCR target of the assay. In one aspect, the cross-contamination controls can be spiked into a sample at sample collection thereby controlling the whole qPCR sample processing workflow.

The present invention provides qPCR controls that can be used starting after the extraction step (e.g., by spiking the extract with the control constructs) or in every step of the qPCR analysis of an unknown test sample (e.g., from nucleic acid extraction to nucleic acid purification to the qPCR itself). In one embodiment, nucleic acid constructs comprising a barcode sequence fragment are provided that can be encapsulated in a simulated cell membrane (e.g., a simulated bacterial cell membrane or eukaryotic cell membrane), or embedded directly in the genome of an organism for use as qPCR spike-in controls. In one aspect, the barcode sequence fragment comprises a unique sequence not present in any known genome. In one embodiment, the qPCR reaction controls can be spiked into the unknown test sample prior to or after nucleic acid extraction and then can be detected in the final samples during qPCR amplification. In another embodiment, different nucleic acid constructs (i.e., with different barcode sequence fragments) can be spiked into different qPCR samples so that cross-contamination of samples or sample swapping can be detected.

In one embodiment, the barcode sequence fragment for use in qPCR can be flanked by universal sequence fragments. The universal sequence fragments can add length to the nucleic acid construct. The barcode sequence fragment is flanked by primer binding site fragments (i.e., directly or indirectly linked to the barcode sequence fragment) so that the nucleic acid construct comprising the barcode sequence fragment can be amplified during qPCR.

In various embodiments, samples with microorganisms containing nucleic acids (e.g., DNA), or samples with other sources of nucleic acids, may be analyzed by qPCR using the control compositions described herein. The samples can be, for example, selected from the group consisting of urine, nasal secretions, nasal washes, inner ear fluids, bronchial lavages, bronchial washes, alveolar lavages, spinal fluid, bone marrow aspirates, sputum, pleural fluids, synovial fluids, pericardial fluids, peritoneal fluids, saliva, tears, gastric secretions, a stool sample, reproductive tract secretions, lymph fluid, whole blood, serum, plasma, a tissue sample, a soil sample, a water sample, a food sample, an air sample, a plant sample, an industrial waste sample, a surface wipe sample, a dust sample, a hair sample, and an animal sample.

In another embodiment, a method is provided for the use of qPCR spike-in controls that simultaneously 1) control for cross-contamination and/or sample swapping and 2) control for different GC content samples (e.g., low, balanced, and high GC content) and/or for different lysis efficiencies. The barcoded DNA molecules are flanked, directly or indirectly, by primer binding site fragments. In one aspect, barcoded DNA molecules are produced with different GC contents, using GC content fragments. In another embodiment, the barcode sequence fragments and the GC content fragments are flanked by universal sequence fragments and the universal sequence fragments are flanked by primer binding site fragments. In another embodiment, the nucleic acid construct is encapsulated in a simulated cell membrane. In this embodiment, the barcode sequence fragments can be used to verify that no cross-contamination or sample swapping occurred during sample preparation or processing. Also in this embodiment, the different GC content fragments (e.g., low, balanced, and high GC content) have the same barcode sequence fragment at each GC percentage (e.g., low, balanced, and high GC content), but in different samples, the barcode sequence fragments are unique. In this embodiment, the GC content fragments can be used to control for GC content bias for example for the polymerase used in qPCR. In this embodiment, the encapsulation method can also be varied to control for different resistances to lysis to mimic, for example, Gram positive, Gram negative, and fungal cell walls. In this encapsulation embodiment, the type of encapsulation method can be correlated to a unique barcode sequence fragment in the nucleic acid construct to enable differentiation during qPCR.

The following clauses, and combinations thereof, provide various additional illustrative aspects of the invention described herein. The various embodiments described in any other section of this patent application, including the section titled “DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS” and the “EXAMPLES” are applicable to any of the following embodiments of the invention described in the numbered clauses below.

1. A qPCR control composition, said control composition comprising a nucleic acid construct comprising at least one barcode sequence fragment wherein the nucleic acid construct further comprises at least a first and a second primer binding site fragment. 2. The control composition of clause 1 wherein the control composition is used to determine if cross-contamination between qPCR samples has occurred. 3. The control composition of clause 1 wherein the control composition is used to determine if sample swapping has occurred during analysis by qPCR. 4. The control composition of any one of clauses 1 to 3 wherein the nucleic acid construct is a deoxyribonucleic acid construct. 5. The control composition of any one of clauses 1 to 4 wherein the nucleic acid construct comprises at least one universal sequence fragment to add length to the nucleic acid construct. 6. The control composition of clause 5 wherein the nucleic acid construct comprises a first universal sequence fragment linked to the 5′ end of the barcode sequence fragment and a second universal sequence fragment linked to the 3′ end of the barcode sequence fragment. 7. The control composition of any one of clauses 1 to 6 in combination with a probe. 8. The control composition of clause 6 wherein the first primer binding site fragment is linked at its 3′-end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of the second universal sequence fragment. 9. The control composition of any one of clauses 1 to 8 wherein the primer binding site fragments range in length from about 15 base pairs to about 30 base pairs. 10. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 300 base pairs. 11. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 250 base pairs. 12. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 200 base pairs. 13. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 160 base pairs. 14. The control composition of any one of clauses 1 to 13 wherein the nucleic acid construct is encapsulated. 15. The control composition of clause 14 wherein the nucleic acid construct is encapsulated in a liposome. 16. The control composition of clause 15 wherein the liposome comprises a lipid selected from the group consisting of cholesterol, a lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a phospholipid, and combinations thereof. 17. The control composition of any one of clauses 1 to 13 wherein the nucleic acid construct is incorporated into the genome of a microorganism. 18. The control composition of any one of clauses 1 to 17 wherein the barcode sequence fragment comprises a unique sequence not present in any known genome. 19. The control composition of any one of clauses 1 to 16 wherein the nucleic acid construct is incorporated into a plasmid. 20. A kit comprising the qPCR control composition of any one of clauses 1 to 19. 21. The kit of clause 20 further comprising a reagent for nucleic acid extraction. 22. The kit of clause 20 or 21 further comprising a reagent for nucleic acid purification. 23. The kit of any one of clauses 20 to 22 further comprising a polymerase. 24. The kit of any one of clauses 20 to 23 further comprising a probe. 25. The kit of clause 24 wherein the probe is a TaqMan probe. 26. The kit of any one of clauses 20 to 25 wherein the kit comprises more than one control composition of any one of clauses 1 to 19 wherein each control composition comprises a different nucleic acid construct wherein the different nucleic acid constructs comprise different barcode sequence fragments. 27. A method for monitoring cross-contamination or sample swapping over one or more steps of a qPCR protocol including collection of a sample comprising DNA, DNA extraction from the sample, purification of the extracted DNA, and qPCR, the method comprising,

-   -   a) spiking the sample with a control composition comprising a         nucleic acid construct wherein the nucleic acid construct         comprises at least one barcode sequence fragment, wherein the         nucleic acid construct is a deoxyribonucleic acid construct, and         wherein the nucleic acid construct further comprises at least a         first and a second primer binding site fragment;     -   b) extracting total DNA wherein total DNA comprises the DNA from         the sample and DNA from the nucleic acid construct;     -   c) purifying total DNA;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         28. The method of clause 27 wherein the sample is selected from         the group consisting of urine, nasal secretions, nasal washes,         inner ear fluids, bronchial lavages, bronchial washes, alveolar         lavages, spinal fluid, bone marrow aspirates, sputum, pleural         fluids, synovial fluids, pericardial fluids, peritoneal fluids,         saliva, tears, gastric secretions, a stool sample, reproductive         tract secretions, lymph fluid, whole blood, serum, plasma, a         tissue sample, a soil sample, a water sample, a food sample, an         air sample, a plant sample, an industrial waste sample, a         surface wipe sample, a dust sample, a hair sample, an         agricultural sample, and an animal sample.         29. The method of clause 27 or 28 wherein the method is used to         determine if cross-contamination between samples has occurred.         30. The method of clause 27 or 28 wherein the method is used to         determine if sample swapping has occurred.         31. The method of any one of clauses 27 to 30 wherein the         nucleic acid construct is amplified.         32. The method of any one of clauses 27 to 31 wherein the         nucleic acid construct further comprises at least a first and a         second universal sequence fragment.         33. The method of clause 32 wherein the first universal sequence         fragment is linked to the 5′ end of the barcode sequence         fragment and the second universal sequence fragment is linked to         the 3′ end of the barcode sequence fragment.         34. The method of any one of clauses 27 to 33 wherein the probe         is a TaqMan probe.         35. The method of any one of clauses 33 to 34 wherein the first         primer binding site fragment is linked at its 3′-end to the 5′         end of the first universal sequence fragment and the second         primer binding site fragment is linked at its 5′ end to the 3′         end of the second universal sequence fragment.         36. The method of any one of clauses 27 to 35 wherein the primer         binding site fragments range in length from about 15 base pairs         to about 30 base pairs.         37. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 300 base pairs.         38. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 250 base pairs.         39. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 200 base pairs.         40. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 160 base pairs.         41. The method of any one of clauses 27 to 40 wherein the         nucleic acid construct is encapsulated.         42. The method of clause 41 wherein the nucleic acid construct         is encapsulated in a liposome.         43. The method of clause 42 wherein the liposome comprises a         lipid selected from the group consisting of cholesterol, a         lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a         phospholipid, and combinations thereof.         44. The method of any one of clauses 27 to 40 wherein the         nucleic acid construct is incorporated into the genome of a         microorganism.         45. The method of any one of clauses 27 to 44 wherein the         barcode sequence fragment comprises a unique sequence not         present in any known genome.         46. The method of any one of clauses 27 to 43 wherein the         nucleic acid construct is incorporated into a plasmid.         47. The method of clause 43 wherein the liposome comprises a         peptidoglycan.         48. The method of clause 43 wherein the liposome comprises a         lipopolysaccharide.         49. A qPCR control composition, said control composition         comprising a nucleic acid construct comprising at least one         barcode sequence fragment and at least one GC content fragment,         wherein the nucleic acid construct further comprises at least a         first and a second primer binding site fragment.         50. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 1 to about 40         percent.         51. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 40 to about         60 percent.         52. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 60 to about         100 percent.         53. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least two different percent GC contents.         54. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least three different percent GC contents.         55. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least four different percent GC contents.         56. The control composition of clause 54 wherein the percent GC         contents are about 1 to about 40 percent, about 40 percent to         about 60 percent, and about 60 percent to about 100 percent.         57. The control composition of any one of clauses 49 to 56         wherein the control composition is used to determine if         cross-contamination between samples for qPCR has occurred.         58. The control composition of any one of clauses 49 to 56         wherein the control composition is used to determine if sample         swapping has occurred for qPCR samples.         59. The control composition of any one of clauses 49 to 58         wherein the GC content fragment is used to control for         polymerase GC content bias.         60. The control composition of any one of clauses 49 to 59 in         combination with a probe.         61. The control composition of any one of clauses 49 to 60         wherein the nucleic acid construct is a deoxyribonucleic acid         construct.         62. The control composition of any one of clauses 49 to 61         wherein the nucleic acid construct further comprises at least a         first and a second universal sequence fragment.         63. The control composition of clause 62 wherein the first         universal sequence fragment is linked to the 5′ end of the         barcode sequence fragment, the barcode sequence fragment is         between the first universal sequence fragment and the GC content         fragment, and the second universal sequence fragment is linked         to the 3′ end of the GC content fragment.         64. The control composition of clause 60 wherein the probe is a         TaqMan probe.         65. The control composition of any one of clauses 62 to 64         wherein the first primer binding site fragment is linked at its         3′-end to the 5′ end of the first universal sequence fragment         and the second primer binding site fragment is linked at its 5′         end to the 3′ end of the second universal sequence fragment.         66. The control composition of any one of clauses 49 to 65         wherein the primer binding site fragments range in length from         about 15 base pairs to about 30 base pairs.         67. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 300 base pairs.         68. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 250 base pairs.         69. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 200 base pairs.         70. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 160 base pairs.         71. The control composition of any one of clauses 49 to 70         wherein the nucleic acid construct is encapsulated.         72. The control composition of clause 71 wherein the nucleic         acid construct is encapsulated in a liposome.         73. The control composition of clause 72 wherein the liposome         comprises a lipid selected from the group consisting of         cholesterol, a lipopolysaccharide, a peptidoglycan, a PEG, a         teichoic acid, a phospholipid, and combinations thereof.         74. The control composition of any one of clauses 49 to 73         wherein the barcode sequence fragment comprises a unique         sequence not present in any known genome.         75. The control composition of any one of clauses 49 to 70         wherein the nucleic acid construct is incorporated into the         genome of a microorganism.         76. The control composition of any one of clauses 49 to 74         wherein the nucleic acid construct is incorporated into a         plasmid.         77. A kit comprising the qPCR control composition of any one of         clauses 49 to 76.         78. The kit of clause 77 further comprising a reagent for         nucleic acid extraction.         79. The kit of clause 77 or 78 further comprising a reagent for         nucleic acid purification.         80. The kit of any one of clauses 77 to 79 further comprising a         probe.         81. The kit of clause 80 wherein the probe is a TaqMan probe.         82. The kit of any one of clauses 77 to 81 further comprising a         polymerase.         83. The kit of any one of clauses 77 to 82 wherein the kit         comprises more than one control composition of any one of         clauses 49 to 76 wherein each control composition comprises a         different nucleic acid construct wherein the different nucleic         acid constructs comprise different barcode sequence fragments.         84. The kit of any one of clauses 77 to 83 wherein the kit         comprises more than one control composition of any one of         clauses 49 to 76 and wherein the nucleic acid construct in each         control composition is encapsulated in a different type of         liposome.         85. A method for monitoring sample cross-contamination and/or         sample swapping of nucleic acids during qPCR, the method         comprising,     -   a) extracting DNA from a sample;     -   b) purifying the DNA;     -   c) spiking the sample, after DNA extraction and purification and         before qPCR, with a control composition comprising a nucleic         acid construct wherein the nucleic acid construct comprises at         least one barcode sequence fragment and at least a first and a         second primer binding site fragment, and at least one GC content         fragment, and wherein the nucleic acid construct is a         deoxyribonucleic acid construct, wherein total DNA is obtained         after spiking the sample, and wherein total DNA comprises the         DNA from the sample and the DNA from the nucleic acid construct;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         86. A method for monitoring sample cross-contamination and/or         sample swapping of nucleic acids during qPCR, the method         comprising,     -   a) spiking a sample with a control composition comprising a         nucleic acid construct wherein the nucleic acid construct         comprises at least one barcode sequence fragment and at least a         first and a second primer binding site fragment, and at least         one GC content fragment and wherein the nucleic acid construct         is a deoxyribonucleic acid construct;     -   b) extracting total DNA from the sample wherein total DNA         comprises the DNA from the sample and the DNA from the nucleic         acid construct;     -   c) purifying total DNA;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         87. The method of clause 86 wherein sample cross-contamination         and/or sample swapping can be monitored over all steps of a qPCR         protocol including collection of the sample, extraction of total         DNA, purification of the extracted total DNA, and qPCR.         88. The method of any one of clauses 85 to 87 wherein the sample         is selected from the group consisting of urine, nasal         secretions, nasal washes, inner ear fluids, bronchial lavages,         bronchial washes, alveolar lavages, spinal fluid, bone marrow         aspirates, sputum, pleural fluids, synovial fluids, pericardial         fluids, peritoneal fluids, saliva, tears, gastric secretions, a         stool sample, reproductive tract secretions, lymph fluid, whole         blood, serum, plasma, a tissue sample, a soil sample, a water         sample, a food sample, an air sample, a plant sample, an         industrial waste sample, a surface wipe sample, a dust sample, a         hair sample, an agricultural sample, and an animal sample.         89. The method of any one of clauses 85 to 88 wherein the probe         is a TaqMan probe.         90. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 1 to about 40         percent.         91. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 40 to about 60         percent.         92. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 60 to about 100         percent.         93. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least two different percent GC         contents.         94. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least three different percent GC         contents.         95. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least four different percent GC         contents.         96. The method of clause 94 wherein the GC contents are about 1         to about 40 percent, about 40 percent to about 60 percent, and         about 60 percent to about 100 percent.         97. The method of any one of clauses 85 to 96 wherein the GC         content fragment is used to control for polymerase GC content         bias.         98. The method of any one of clauses 93 to 96 wherein at each of         the different percent GC contents the nucleic acid constructs         comprise the same barcode sequence fragments.         99. The method of any one of clauses 85 to 98 wherein the         barcode sequence fragment comprises a unique sequence not         present in any known genome.         100. The method of any one of clauses 85 to 99 wherein the         nucleic acid construct further comprises at least a first and a         second universal sequence fragment.         101. The method of clause 100 wherein the first universal         sequence fragment is linked to the 5′ end of the barcode         sequence fragment, the barcode sequence fragment is between the         first universal sequence fragment and the GC content fragment,         and the second universal sequence fragment is linked to the 3′         end of the GC content fragment.         102. The method of any one of clauses 85 to 101 wherein the         nucleic acid construct is amplified.         103. The method of clause 100 or 101 wherein the first primer         binding site fragment is linked at its 3′ end to the 5′ end of         the first universal sequence fragment and the second primer         binding site fragment is linked at its 5′ end to the 3′ end of         the second universal sequence fragment.         104. The method of any one of clauses 85 to 103 wherein the         primer binding site fragments range in length from about 15 base         pairs to about 30 base pairs.         105. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 300 base pairs.         106. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 250 base pairs.         107. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 200 base pairs.         108. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 160 base pairs.         109. The method of any one of clauses 85 to 108 wherein the         nucleic acid construct is encapsulated.         110. The method of clause 109 wherein the nucleic acid construct         is encapsulated in a liposome.         111. The method of clause 110 wherein the liposome comprises a         lipid selected from the group consisting of cholesterol, a         lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a         phospholipid, and combinations thereof.         112. The method of any one of clauses 85 to 111 wherein more         than one type of control composition is used in the method.         113. The method of any one of clauses 85 to 111 wherein more         than one type of control composition is used in the method         wherein the nucleic acid construct in each type of control         composition is encapsulated in a different type of liposome.         114. The method of clause 113 wherein each type of control         composition with the nucleic acid construct encapsulated in a         different type of liposome comprises a different barcode         sequence fragment.         115. The method of any one of clauses 85 to 108 wherein the         nucleic acid construct is incorporated into the genome of a         microorganism.         116. The method of any one of clauses 85 to 113 wherein the         nucleic acid construct is incorporated into a plasmid.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows schematically an exemplary nucleic acid construct as described herein comprising the unique barcode sequence fragment (e.g., 24 bases) that is not present in any known genome. The exemplary nucleic acid construct also comprises 10 bp and 12 bp universal sequence fragments and primer binding site fragments at the 5′ and 3′ ends of the nucleic acid construct. A probe with an attached fluorophore for qPCR is also shown. The probe is for hybridization to the barcode sequence fragment.

FIG. 2A shows schematically the exemplary nucleic acid construct of FIG. 1 as described herein cloned into a plasmid.

FIG. 2B shows schematically the exemplary nucleic acid construct of FIG. 1 as described herein inserted into the genome of a microorganism. In one aspect, the microorganism could be modified utilizing gene editing (e.g., CRISPR) so that the natural primer binding sites are removed before inserting the nucleic acid construct described herein into the genome of the microorganism. Unique probes with different fluorophores are also shown with one probe being directed to the native sequence between the natural primer binding sites and one probe being directed to the barcode sequence fragment resulting in quantification of the barcode and the native sequence.

FIG. 2C shows schematically the exemplary nucleic acid construct of FIG. 1 as described herein where the barcode sequence fragment is inserted into the genome of a microorganism between natural primer binding sites. In one aspect, the microorganism could be modified utilizing gene editing (e.g., CRISPR) so that the sequence between the natural primer binding sites is replaced with the barcode. Unique probes with different fluorophores are also shown with one probe being directed to the native sequence between the natural primer binding sites and one probe being directed to the barcode sequence fragment resulting in quantification of the barcode and the native sequence.

FIG. 3A shows schematically the direct encapsulation of the exemplary nucleic acid construct of FIG. 1 as described herein without a plasmid or genome backbone. The nucleic acid construct comprises primer binding site fragments. A probe with an attached fluorophore for qPCR is also shown. The probe is for hybridization to the barcode sequence fragment and is not encapsulated.

FIG. 3B shows schematically the direct encapsulation of the exemplary nucleic acid construct of FIG. 1 as described herein within a plasmid. The nucleic acid construct comprises primer binding site fragments. A probe with an attached fluorophore for qPCR is also shown. The probe is for hybridization to the barcode sequence fragment and is not encapsulated.

FIG. 4 shows a schematic of exemplary spike-in control nucleic acid constructs where the nucleic acid constructs include universal sequence fragments, and where exemplary sample 1 nucleic acid constructs include a barcode sequence fragment (barcode 1), and exemplary sample 2 nucleic acid constructs include a barcode sequence fragment (barcode 2) that is different than the barcode sequence fragment in the sample 1 nucleic acid constructs. The schematic also exemplifies nucleic acid constructs with a low GC content fragment, a balanced GC content fragment, and a high GC content fragment. A forward primer binding site fragment is included in the nucleic acid construct at the 5′ end of the 5′ universal sequence fragment and a reverse primer binding site fragment is included at the 3′ end of the 3′ universal sequence fragment. Both primer binding site fragments are labeled “P”. In this example, each of the probes for each of the six nucleic acid constructs shown diagrammatically is unique and each probe is directed to the barcode sequence fragment in combination with GC content fragment sequence. The fluorophores for each of the probes are also different so that the different GC content fragments and the different barcode sequence fragments can be distinguished.

FIG. 5 shows schematically the direct encapsulation of an exemplary nucleic acid construct of FIG. 1 as described herein. The nucleic acid construct comprises primer binding site fragments. Probes with attached fluorophores for qPCR are also shown. The probes are for hybridization to the barcode sequence fragment and are not encapsulated. Unique probes with different fluorophores are shown with one probe being directed to the barcode sequence fragment in the first liposome composition shown, and the other probe being directed to the barcode sequence fragment in the second liposome composition shown, resulting in the ability to distinguish the nucleic acid constructs in the two types of liposomes.

FIG. 6 shows a schematic of exemplary spike-in control nucleic acid constructs encapsulated within simulated cell membranes highly resistant to lysis (A) and within non-resistant (easy to lyse) simulated cell membranes (B). The highly resistant cell membranes (e.g., liposomes) include, for example, lipid formulations with higher crystal transition temperatures, and higher amounts of LPS, PG, teichoic acids, PEG, cholesterol, and/or cationic lipids to condense the nucleic acid constructs. The non-resistant simulated cell membranes may, for example, omit the preceding ingredients or include them to a lesser degree. The barcode sequence fragment (D) is different in cell membranes highly resistant to lysis (A) versus non-resistant (easy to lyse) simulated cell membranes (B). The schematic also exemplifies nucleic acid constructs with a low GC content fragment, a balanced GC content fragment, and a high GC content fragment. A forward primer binding site fragment is included in the nucleic acid construct at the 5′ end of the 5′ universal sequence fragment and a reverse primer binding site fragment is included at the 3′ end of the 3′ universal sequence fragment. Both primer binding site fragments are labeled “P”. The probes are shown and are analogous to those shown in FIG. 4 and are not encapsulated.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention provides qPCR controls that can be used starting after the sample extraction step (e.g., by spiking the extract with the control constructs) or in every step of analysis of an unknown test sample (e.g., from nucleic acid extraction to nucleic acid purification to qPCR). In one embodiment, nucleic acid constructs comprising a barcode sequence fragment are provided that can be encapsulated in a simulated cell membrane (e.g., a simulated bacterial cell membrane or eukaryotic cell membrane), or embedded directly in the genome of an organism for use as spike-in qPCR controls. In one aspect, the barcode sequence fragment comprises a unique sequence not present in any known genome. In one embodiment, the qPCR controls can be spiked in the unknown test sample prior to or after nucleic acid extraction and then can be detected in the qPCR samples during amplification. In another embodiment, different nucleic acid constructs (i.e., with different barcode sequence fragments) can be spiked in different samples so that cross-contamination of samples or sample swapping can be detected.

In one embodiment, the barcode sequence fragment can be flanked at its 5′ or 3′ end, or both, by universal sequence fragments. The universal sequence fragments can add length to the nucleic acid construct. The barcode sequence fragment is flanked by primer binding site fragments (i.e., directly linked to the barcode sequence fragment, or indirectly linked to the barcode sequence fragment through the use of universal sequence fragments) so that the nucleic acid construct comprising the barcode sequence fragment can be amplified during qPCR. In another embodiment, a set of different nucleic acid construct spike-ins with different barcode sequence fragments, and different probes directed to the barcode sequence fragments, and in some embodiments directed to additional sequences such as GC content fragment sequences (see FIG. 4 ), can be used to allow for multiplexing of nucleic acid constructs with different barcode sequence fragments in a qPCR assay.

In various embodiments, samples with microorganisms containing nucleic acids (e.g., DNA), or samples with other sources of nucleic acids, may be analyzed by qPCR using the control compositions for qPCR described herein. The samples can be, for example, selected from the group consisting of urine, nasal secretions, nasal washes, inner ear fluids, bronchial lavages, bronchial washes, alveolar lavages, spinal fluid, bone marrow aspirates, sputum, pleural fluids, synovial fluids, pericardial fluids, peritoneal fluids, saliva, tears, gastric secretions, a stool sample, reproductive tract secretions, lymph fluid, whole blood, serum, plasma, hair, a tissue sample, a soil sample, a water sample, a food sample, an air sample, a plant sample, an industrial waste sample, a surface wipe sample, and an animal sample.

In another embodiment, compositions and methods are provided for the use of spike-in controls that simultaneously 1) control for cross-contamination and/or sample swapping and 2) control for different GC content samples (e.g., low, balanced, and high GC content) and/or for different lysis efficiencies. In one aspect, barcoded DNA molecules are produced with different GC contents, using GC content fragments, wherein barcode sequence fragments and GC content fragments are flanked by primer binding site fragments. In another embodiment, universal sequence fragments are included. In yet another embodiment, the nucleic acid construct can be encapsulated in a simulated cell membrane. In this embodiment, the barcode sequence fragments can be used to verify that no cross-contamination or sample swapping occurred during sample preparation or processing. In this quantitation embodiment, the different GC content fragments (e.g., low, balanced, and high GC content) have the same barcode sequence fragment at each GC percentage (e.g., low, balanced, and high GC content), but for each different sample, the barcode sequence fragments are unique. In this embodiment, the encapsulation method can also be varied to control for different resistances to lysis to mimic, for example, Gram-positive bacterial cell walls, Gram-negative bacterial cell walls, and fungal cell walls. In this encapsulation embodiment, the type of encapsulation method can be correlated to a unique barcode sequence fragment in the nucleic acid construct to enable differentiation in qPCR.

In one embodiment, the nucleic acid construct can be constructed with a first universal sequence fragment linked at the 5′ end of a unique barcode sequence fragment, a GC content fragment (e.g., with high, balanced, or low GC content) linked to the 3′ end of the barcode sequence fragment, a second universal sequence fragment linked at the 3′ end of the GC content fragment, and 5′ and 3′ primer binding site fragments flanking the universal sequence fragments. In this embodiment, the universal sequence fragments can add length to the nucleic acid construct. In another embodiment, the universal sequence fragments are lacking. In yet another embodiment, the GC content fragment is lacking. In still another embodiment, both the universal sequence fragments and the GC content fragment are lacking. In these embodiments, the unique barcode sequence fragment is a sequence that is not present in any known genome.

An exemplary GC content fragment can contain about 60 to about 100 percent GC content for high GC content, about 40 to about 60 percent GC content for balanced GC content, and about 1 to about 40 percent GC content for low GC content. In various embodiments, the nucleic acid constructs can either be encapsulated to spike into samples at sample collection and control for full sample preparation and processing or can be unencapsulated and can be spiked in after extraction to control for subsequent steps in qPCR. In one aspect, two or more mixtures of three different GC content fragment constructs can be used (e.g., for different samples with each having a unique barcode sequence fragment).

The following clauses, and combinations thereof, provide various additional illustrative aspects of the invention described herein. The various embodiments described in any other section of this patent application, including the summary portion of the section titled “BACKGROUND AND SUMMARY”, the “EXAMPLES”, and this “DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS” section of the application are applicable to any of the following embodiments of the invention described in the numbered clauses below.

1. A qPCR control composition, said control composition comprising a nucleic acid construct comprising at least one barcode sequence fragment wherein the nucleic acid construct further comprises at least a first and a second primer binding site fragment. 2. The control composition of clause 1 wherein the control composition is used to determine if cross-contamination between qPCR samples has occurred. 3. The control composition of clause 1 wherein the control composition is used to determine if sample swapping has occurred during analysis by qPCR. 4. The control composition of any one of clauses 1 to 3 wherein the nucleic acid construct is a deoxyribonucleic acid construct. 5. The control composition of any one of clauses 1 to 4 wherein the nucleic acid construct comprises at least one universal sequence fragment to add length to the nucleic acid construct. 6. The control composition of clause 5 wherein the nucleic acid construct comprises a first universal sequence fragment linked to the 5′ end of the barcode sequence fragment and a second universal sequence fragment linked to the 3′ end of the barcode sequence fragment. 7. The control composition of any one of clauses 1 to 6 in combination with a probe. 8. The control composition of clause 6 wherein the first primer binding site fragment is linked at its 3′-end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of the second universal sequence fragment. 9. The control composition of any one of clauses 1 to 8 wherein the primer binding site fragments range in length from about 15 base pairs to about 30 base pairs. 10. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 300 base pairs. 11. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 250 base pairs. 12. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 200 base pairs. 13. The control composition of any one of clauses 1 to 9 wherein the nucleic acid construct ranges in length from about 80 base pairs to about 160 base pairs. 14. The control composition of any one of clauses 1 to 13 wherein the nucleic acid construct is encapsulated. 15. The control composition of clause 14 wherein the nucleic acid construct is encapsulated in a liposome. 16. The control composition of clause 15 wherein the liposome comprises a lipid selected from the group consisting of cholesterol, a lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a phospholipid, and combinations thereof. 17. The control composition of any one of clauses 1 to 13 wherein the nucleic acid construct is incorporated into the genome of a microorganism. 18. The control composition of any one of clauses 1 to 17 wherein the barcode sequence fragment comprises a unique sequence not present in any known genome. 19. The control composition of any one of clauses 1 to 16 wherein the nucleic acid construct is incorporated into a plasmid. 20. A kit comprising the qPCR control composition of any one of clauses 1 to 19. 21. The kit of clause 20 further comprising a reagent for nucleic acid extraction. 22. The kit of clause 20 or 21 further comprising a reagent for nucleic acid purification. 23. The kit of any one of clauses 20 to 22 further comprising a polymerase. 24. The kit of any one of clauses 20 to 23 further comprising a probe. 25. The kit of clause 24 wherein the probe is a TaqMan probe. 26. The kit of any one of clauses 20 to 25 wherein the kit comprises more than one control composition of any one of clauses 1 to 19 wherein each control composition comprises a different nucleic acid construct wherein the different nucleic acid constructs comprise different barcode sequence fragments. 27. A method for monitoring cross-contamination or sample swapping over one or more steps of a qPCR protocol including collection of a sample comprising DNA, DNA extraction from the sample, purification of the extracted DNA, and qPCR, the method comprising,

-   -   a) spiking the sample with a control composition comprising a         nucleic acid construct wherein the nucleic acid construct         comprises at least one barcode sequence fragment, wherein the         nucleic acid construct is a deoxyribonucleic acid construct, and         wherein the nucleic acid construct further comprises at least a         first and a second primer binding site fragment;     -   b) extracting total DNA wherein total DNA comprises the DNA from         the sample and DNA from the nucleic acid construct;     -   c) purifying total DNA;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         28. The method of clause 27 wherein the sample is selected from         the group consisting of urine, nasal secretions, nasal washes,         inner ear fluids, bronchial lavages, bronchial washes, alveolar         lavages, spinal fluid, bone marrow aspirates, sputum, pleural         fluids, synovial fluids, pericardial fluids, peritoneal fluids,         saliva, tears, gastric secretions, a stool sample, reproductive         tract secretions, lymph fluid, whole blood, serum, plasma, a         tissue sample, a soil sample, a water sample, a food sample, an         air sample, a plant sample, an industrial waste sample, a         surface wipe sample, a dust sample, a hair sample, an         agricultural sample, and an animal sample.         29. The method of clause 27 or 28 wherein the method is used to         determine if cross-contamination between samples has occurred.         30. The method of clause 27 or 28 wherein the method is used to         determine if sample swapping has occurred.         31. The method of any one of clauses 27 to 30 wherein the         nucleic acid construct is amplified.         32. The method of any one of clauses 27 to 31 wherein the         nucleic acid construct further comprises at least a first and a         second universal sequence fragment.         33. The method of clause 32 wherein the first universal sequence         fragment is linked to the 5′ end of the barcode sequence         fragment and the second universal sequence fragment is linked to         the 3′ end of the barcode sequence fragment.         34. The method of any one of clauses 27 to 33 wherein the probe         is a TaqMan probe.         35. The method of any one of clauses 33 to 34 wherein the first         primer binding site fragment is linked at its 3′-end to the 5′         end of the first universal sequence fragment and the second         primer binding site fragment is linked at its 5′ end to the 3′         end of the second universal sequence fragment.         36. The method of any one of clauses 27 to 35 wherein the primer         binding site fragments range in length from about 15 base pairs         to about 30 base pairs.         37. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 300 base pairs.         38. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 250 base pairs.         39. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 200 base pairs.         40. The method of any one of clauses 27 to 36 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 160 base pairs.         41. The method of any one of clauses 27 to 40 wherein the         nucleic acid construct is encapsulated.         42. The method of clause 41 wherein the nucleic acid construct         is encapsulated in a liposome.         43. The method of clause 42 wherein the liposome comprises a         lipid selected from the group consisting of cholesterol, a         lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a         phospholipid, and combinations thereof.         44. The method of any one of clauses 27 to 40 wherein the         nucleic acid construct is incorporated into the genome of a         microorganism.         45. The method of any one of clauses 27 to 44 wherein the         barcode sequence fragment comprises a unique sequence not         present in any known genome.         46. The method of any one of clauses 27 to 43 wherein the         nucleic acid construct is incorporated into a plasmid.         47. The method of clause 43 wherein the liposome comprises a         peptidoglycan.         48. The method of clause 43 wherein the liposome comprises a         lipopolysaccharide.         49. A qPCR control composition, said control composition         comprising a nucleic acid construct comprising at least one         barcode sequence fragment and at least one GC content fragment,         wherein the nucleic acid construct further comprises at least a         first and a second primer binding site fragment.         50. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 1 to about 40         percent.         51. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 40 to about         60 percent.         52. The control composition of clause 49 wherein one or more of         the GC content fragments has a GC content of about 60 to about         100 percent.         53. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least two different percent GC contents.         54. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least three different percent GC contents.         55. The control composition of any one of clauses 49 to 52         comprising nucleic acid constructs with GC content fragments         with at least four different percent GC contents.         56. The control composition of clause 54 wherein the percent GC         contents are about 1 to about 40 percent, about 40 percent to         about 60 percent, and about 60 percent to about 100 percent.         57. The control composition of any one of clauses 49 to 56         wherein the control composition is used to determine if         cross-contamination between samples for qPCR has occurred.         58. The control composition of any one of clauses 49 to 56         wherein the control composition is used to determine if sample         swapping has occurred for qPCR samples.         59. The control composition of any one of clauses 49 to 58         wherein the GC content fragment is used to control for         polymerase GC content bias.         60. The control composition of any one of clauses 49 to 59 in         combination with a probe.         61. The control composition of any one of clauses 49 to 60         wherein the nucleic acid construct is a deoxyribonucleic acid         construct.         62. The control composition of any one of clauses 49 to 61         wherein the nucleic acid construct further comprises at least a         first and a second universal sequence fragment.         63. The control composition of clause 62 wherein the first         universal sequence fragment is linked to the 5′ end of the         barcode sequence fragment, the barcode sequence fragment is         between the first universal sequence fragment and the GC content         fragment, and the second universal sequence fragment is linked         to the 3′ end of the GC content fragment.         64. The control composition of clause 60 wherein the probe is a         TaqMan probe.         65. The control composition of any one of clauses 62 to 64         wherein the first primer binding site fragment is linked at its         3′-end to the 5′ end of the first universal sequence fragment         and the second primer binding site fragment is linked at its 5′         end to the 3′ end of the second universal sequence fragment.         66. The control composition of any one of clauses 49 to 65         wherein the primer binding site fragments range in length from         about 15 base pairs to about 30 base pairs.         67. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 300 base pairs.         68. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 250 base pairs.         69. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 200 base pairs.         70. The control composition of any one of clauses 49 to 66         wherein the nucleic acid construct ranges in length from about         80 base pairs to about 160 base pairs.         71. The control composition of any one of clauses 49 to 70         wherein the nucleic acid construct is encapsulated.         72. The control composition of clause 71 wherein the nucleic         acid construct is encapsulated in a liposome.         73. The control composition of clause 72 wherein the liposome         comprises a lipid selected from the group consisting of         cholesterol, a lipopolysaccharide, a peptidoglycan, a PEG, a         teichoic acid, a phospholipid, and combinations thereof.         74. The control composition of any one of clauses 49 to 73         wherein the barcode sequence fragment comprises a unique         sequence not present in any known genome.         75. The control composition of any one of clauses 49 to 70         wherein the nucleic acid construct is incorporated into the         genome of a microorganism.         76. The control composition of any one of clauses 49 to 74         wherein the nucleic acid construct is incorporated into a         plasmid.         77. A kit comprising the qPCR control composition of any one of         clauses 49 to 76.         78. The kit of clause 77 further comprising a reagent for         nucleic acid extraction.         79. The kit of clause 77 or 78 further comprising a reagent for         nucleic acid purification.         80. The kit of any one of clauses 77 to 79 further comprising a         probe.         81. The kit of clause 80 wherein the probe is a TaqMan probe.         82. The kit of any one of clauses 77 to 81 further comprising a         polymerase.         83. The kit of any one of clauses 77 to 82 wherein the kit         comprises more than one control composition of any one of         clauses 49 to 76 wherein each control composition comprises a         different nucleic acid construct wherein the different nucleic         acid constructs comprise different barcode sequence fragments.         84. The kit of any one of clauses 77 to 83 wherein the kit         comprises more than one control composition of any one of         clauses 49 to 76 and wherein the nucleic acid construct in each         control composition is encapsulated in a different type of         liposome.         85. A method for monitoring sample cross-contamination and/or         sample swapping of nucleic acids during qPCR, the method         comprising,     -   a) extracting DNA from a sample;     -   b) purifying the DNA;     -   c) spiking the sample, after DNA extraction and purification and         before qPCR, with a control composition comprising a nucleic         acid construct wherein the nucleic acid construct comprises at         least one barcode sequence fragment and at least a first and a         second primer binding site fragment, and at least one GC content         fragment, and wherein the nucleic acid construct is a         deoxyribonucleic acid construct, wherein total DNA is obtained         after spiking the sample, and wherein total DNA comprises the         DNA from the sample and the DNA from the nucleic acid construct;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         86. A method for monitoring sample cross-contamination and/or         sample swapping of nucleic acids during qPCR, the method         comprising,         a) spiking a sample with a control composition comprising a         nucleic acid construct wherein the nucleic acid construct         comprises at least one barcode sequence fragment and at least a         first and a second primer binding site fragment, and at least         one GC content fragment and wherein the nucleic acid construct         is a deoxyribonucleic acid construct;     -   b) extracting total DNA from the sample wherein total DNA         comprises the DNA from the sample and the DNA from the nucleic         acid construct;     -   c) purifying total DNA;     -   d) performing qPCR on the extracted, purified total DNA; and     -   e) detecting the nucleic acid construct in total DNA using a         probe.         87. The method of clause 86 wherein sample cross-contamination         and/or sample swapping can be monitored over all steps of a qPCR         protocol including collection of the sample, extraction of total         DNA, purification of the extracted total DNA, and qPCR.         88. The method of any one of clauses 85 to 87 wherein the sample         is selected from the group consisting of urine, nasal         secretions, nasal washes, inner ear fluids, bronchial lavages,         bronchial washes, alveolar lavages, spinal fluid, bone marrow         aspirates, sputum, pleural fluids, synovial fluids, pericardial         fluids, peritoneal fluids, saliva, tears, gastric secretions, a         stool sample, reproductive tract secretions, lymph fluid, whole         blood, serum, plasma, a tissue sample, a soil sample, a water         sample, a food sample, an air sample, a plant sample, an         industrial waste sample, a surface wipe sample, a dust sample, a         hair sample, an agricultural sample, and an animal sample.         89. The method of any one of clauses 85 to 88 wherein the probe         is a TaqMan probe.         90. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 1 to about 40         percent.         91. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 40 to about 60         percent.         92. The method of any one of clauses 85 to 89 wherein one of the         GC content fragments has a GC content of about 60 to about 100         percent.         93. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least two different percent GC         contents.         94. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least three different percent GC         contents.         95. The method of any one of clauses 85 to 92 wherein the         control composition comprises nucleic acid constructs with GC         content fragments with at least four different percent GC         contents.         96. The method of clause 94 wherein the GC contents are about 1         to about 40 percent, about 40 percent to about 60 percent, and         about 60 percent to about 100 percent.         97. The method of any one of clauses 85 to 96 wherein the GC         content fragment is used to control for polymerase GC content         bias.         98. The method of any one of clauses 93 to 96 wherein at each of         the different percent GC contents the nucleic acid constructs         comprise the same barcode sequence fragments.         99. The method of any one of clauses 85 to 98 wherein the         barcode sequence fragment comprises a unique sequence not         present in any known genome.         100. The method of any one of clauses 85 to 99 wherein the         nucleic acid construct further comprises at least a first and a         second universal sequence fragment.         101. The method of clause 100 wherein the first universal         sequence fragment is linked to the 5′ end of the barcode         sequence fragment, the barcode sequence fragment is between the         first universal sequence fragment and the GC content fragment,         and the second universal sequence fragment is linked to the 3′         end of the GC content fragment.         102. The method of any one of clauses 85 to 101 wherein the         nucleic acid construct is amplified.         103. The method of clause 100 or 101 wherein the first primer         binding site fragment is linked at its 3′ end to the 5′ end of         the first universal sequence fragment and the second primer         binding site fragment is linked at its 5′ end to the 3′ end of         the second universal sequence fragment.         104. The method of any one of clauses 85 to 103 wherein the         primer binding site fragments range in length from about 15 base         pairs to about 30 base pairs.         105. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 300 base pairs.         106. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 250 base pairs.         107. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 200 base pairs.         108. The method of any one of clauses 85 to 104 wherein the         nucleic acid construct ranges in length from about 80 base pairs         to about 160 base pairs.         109. The method of any one of clauses 85 to 108 wherein the         nucleic acid construct is encapsulated.         110. The method of clause 109 wherein the nucleic acid construct         is encapsulated in a liposome.         111. The method of clause 110 wherein the liposome comprises a         lipid selected from the group consisting of cholesterol, a         lipopolysaccharide, a peptidoglycan, a PEG, a teichoic acid, a         phospholipid, and combinations thereof.         112. The method of any one of clauses 85 to 111 wherein more         than one type of control composition is used in the method.         113. The method of any one of clauses 85 to 111 wherein more         than one type of control composition is used in the method         wherein the nucleic acid construct in each type of control         composition is encapsulated in a different type of liposome.         114. The method of clause 113 wherein each type of control         composition with the nucleic acid construct encapsulated in a         different type of liposome comprises a different barcode         sequence fragment.         115. The method of any one of clauses 85 to 108 wherein the         nucleic acid construct is incorporated into the genome of a         microorganism.         116. The method of any one of clauses 85 to 113 wherein the         nucleic acid construct is incorporated into a plasmid.

Control compositions for qPCR and methods of their use are provided herein. The quantitative polymerase chain reaction (qPCR) has been developed to analyze nucleic acids in a laboratory. qPCR for quantitation of nucleic acids is a powerful technique, for example, for pathogen detection and quantitation, including for biosurveillance and disease diagnosis. However, the field suffers from a lack of standards for use in qPCR methods and devices that can be used to monitor cross-contamination and sample-swapping. Currently, researchers are able to detect and identify nucleic acids from, for example, pathogens using qPCR, but are unable to monitor sample cross-contamination and sample swapping throughout the qPCR protocol. More effective standards are also needed for monitoring sample cross-contamination and sample swapping in a qPCR protocol after the extraction process.

In one embodiment, control compositions for qPCR are provided. The control compositions comprise a nucleic acid construct comprising at least one barcode sequence fragment and at least a first and a second primer binding site fragment. The barcode sequence fragment comprises a unique sequence not found in any known genome. In one embodiment, the control composition is used to determine if cross-contamination between samples for qPCR has occurred. In another embodiment, the control composition is used to determine if sample swapping during qPCR has occurred. In one aspect, the nucleic acid construct is a deoxyribonucleic acid construct. In another aspect, the nucleic acid construct is a ribonucleic acid. In another embodiment, the nucleic acid construct is incorporated into a plasmid. In yet another aspect, the nucleic acid construct is incorporated into the genome of an organism.

In various embodiments, the barcode sequence fragment can be from about 10 to about 35 base pairs in length, about 10 to about 34 base pairs in length, about 10 to about 33 base pairs in length, about 10 to about 32 base pairs in length, about 10 to about 31 base pairs in length, about 10 to about 30 base pairs in length, about 10 to about 29 base pairs in length, about 10 to about 28 base pairs in length, about 10 to about 27 base pairs in length, about 10 to about 26 base pairs in length, about 10 to about 25 base pairs in length, about 10 to about 24 base pairs in length, about 10 to about 15 base pairs in length, about 21 to about 28 base pairs in length, about 21 to about 27 base pairs in length, about 21 to about 26 base pairs in length, about 21 to about 25 base pairs in length, about 22 to about 28 base pairs in length, about 22 to about 27 base pairs in length, about 22 to about 26 base pairs in length, about 22 to about 25 base pairs in length, about 23 to 25 base pairs in length, or about 24 base pairs in length.

Various embodiments of barcode sequence fragments are shown below in Table 1 (labeled barcode sequence fragments). These barcode sequence fragments can be used alone or in combinations of, for example, two or more barcode sequence fragments. Additional barcode sequence fragments are shown in Table 2 between the bolded fragments and within the exemplary nucleic acid constructs having SEQ ID NOS:1 to 384.

TABLE 1 Barcode Barcode Barcode Barcode Barcode Barcode Sequence Sequence Sequence Sequence Sequence Sequence Fragments Fragments Fragments Fragments Fragments Fragments TGGTCAACGATA CATCGCGTTGAC ACGTAACCACGT CTTCTTCGCCCT GACGGCTATGTT GTCATTGGGCTA ATCGCACAGTAA GCACATAGTCGT GTCGGAAATTGT CAGGCATAACAT TCTCTTTCGACA AGAGACGCGTAG GTCGTGTAGCCT GGCAAATACACT TCTAACGAGTGC ATGTGGCGTGTT GATTAGGTTCCG TTAATGGATCGG AGCGGAGGTTAG GTCATGCTCCAG CATCTGGGCAAT GTGCGGTTCACT CTACTCCACGAG ATATTGGCAGCC ATCCTTTGGTTC CCTAGTAAGCTG TGTCCGTGGATC CCTCACTAGCGA GGTGCAGACAGA TCGCATGGATAC TACAGCGCATAC TTACCGACGAGT ACTCGGCCAACT AGCTGATAGTTG CCGTACCGTATG CAACAATGCCAA ACCGGTATGTAC GCTTAGATGTAG GTTGGTTGGCAT GCTCTAGTAACG ATGTCCGACCAA GCCCGACATATA AATTGTGTCGGA AAGACGTAGCGG TTCCACACGTGG TGGTCCTACAAG AGATGGGACTGG GATTGAACGCTA TGCATACACTGG TTACCTTACACC AACCCAGATGAT CGCTATCCAGAC GTGCCCACTTGA AGTATTCGCGCA AGTCGAACGAGG TGACTAATGGCC GTAGTGTCAACA GCTTACGTAGGT ACCGAACAATCC TGCCAACAACAA ACCAGTGACTCA CTCTCTCACTTG TGGAGAGGAGAT AGTTGGTTACGA GTCTACCACGCA CTAAAGTAGCAC GAATACCAAGTC ATTGCAAGCAAC CGTATAAATGCG CTCTACGAACAG TCGCGTCCAGTA AGTGCTAGGTTA GTAGATCGTGTA CACGTGACATGT AATACAGACCTG CCTGTGTTGGTG GCCTGATTAAGC CGGAAACTCCAT TAACGTGTGTGC CACAGTTGAAGT GACTCAACCAGT GATGGGAGGACT ACGTATTCGAAG AGGAAAGCCAGA CATTATGGCGTG CTAGGATCACTG GGAAGAAGTAGC CAGAATCGCTCA CGGCTACTATGC GTCTGACGGTCT CCAATACGCCTG GATGACCCAAAT ATCGATCCACAG TGGCACTGGTTA AGTTCGGCATTG GAAACCAAGCTT GATCTGCGATCC ACCGGAGTAGGA ACACCGCACAAT GGCAGTGTTAAT TTGGGAGCGAAG TCATCACGGGCT CAGCTCATCAGC TGAGGACTACCT GTCTCCTCCCTT AACCCGTCGTCA TGTTCGCCCAGA TGTTCTGAGACG CAAACAACAGCT CAATCGGCTTGC GTAGCACTCATG AGAGGAGTCGAC CGCGTATCTCAG ATAGCACCAGAT GCAACACCATCC AACACTCGATCG CACCTGTAGTAG TAAGTCGGCCTA CGAAAGCATTCC ATCTCGCTGGGT GCGATATATCGC TGACCGGCTGTT CACGAGCTACTC CAGGGTAGGGTA CCGGACAAGAAG GCGCGTGTATCT CGAGCAATCCTA GGAGGAGCAATA TCTCGATAAGCG CATGGGTGTTAC CGATCCGATCTG AACGCGAAATTC AGTCGTGCACAT AGCGACGAAGAC TAGACACCGTGT GATGCCTAATGA TGCATCGCGTCA ATCTGGACGATC GTATCTGCGCGT CTTCCCTAACTC AGACAAGCTTCC TTATCGGGCATG ATGGACCTAGCT CCAGCTGGACTT CGAGGGAAAGTC TGGAAGAACGGC TCCGCAACCTGA TGGACATAAACC AGGAATACTCAC CTCTAACCTCTA CAAATTCGGGAT GCTAGACACTAC TCACTTGGTGCG TGACCTCAAGAC CTACCTTGAGGA CAACCGAGATTA AGATTGACCAAC TTGGATTGAACG TTATGTACGGCG GCCAAATCGCTC CGTGTTATGTGG GATTCGAGTGTC AGTTACGAGCTA GATATACCAGTG TTGGACGTCCAC TCAAAGCTCAAG GTACGCACAGTT GGTAACCTCTGA GCATATGCACTG AACAAACTGCCA TCCAGGGCTATA TACCAATCGGTG TGGACTCAGCTA AGCGAACCTGTT CAACTCCCGTGA GTAGACATGTGT GCGTAGAGAGAC GTACTCGAACCA ACGCGCTAAATC ACATGCACATGC TTGCGTTAGCAG TACAGTTACGCG GAAACTCCTAGA TTCCGGCGATTG GACCTGAATACA CCTTACCTCCTC TACGAGCCCTAA CAAGCCCTAGTA ATCGGGCTTAAC GACATGCGGAGA ACGTTTGTGGCA ACACTGGTCCTG CACTACGCTAGA TAGTGTCGGATC TACGCCCATCAG CGCACCCATACA GCTTAACGTGCC AGCTTGAATCAG TGCAGTCCTCGA CTGAGCTCTGCA AAGATCGTACTG ACATTGAAGCGT GAATGGATGGGC TAAAGCGAGGAG ACCATAGCTCCG CTTCGACTTTCC ACTCATCTTCCA GACGACATTTAG CATGAACAGTGT CGACAACTTGTG TCGACATCTCTT GTCATAAGAACC GAGATACAGTTC CCAACTACTCGG GACTAGTCAGCT CGCTGGCTTTAG GAACACTTTGGA GTCCGCAAGTTA GCATGCATCCCA CCGTTATCAGCG CAAGAAATTCGC GTGATACCCGCT GAGCCATCTGTA CGTAGAGCTCTC GATCTAATCGAG TATGGCCAAACC AAGCTCTCCCAG CCAGTTCCAAAG TTGGGTACACGT CCTCTGAGAGCT AATCTTGCGCCG TGCCTAAGATCG TGGATCTGTCCG GTCTGGATTGAA AAGGCGCTCCTT CCTCGATGCAGT GGAAATCCCATC TTAACTGGAAGC CCTACTCGGTGA GCGCAATAGTAT TAATACGGATCG GCGGACTATTCA GACCGTCAATAC ATTCGAGCTGTG ATACCGTCTTTC AGCGTTGTCCAA TCGGAATTAGAC CGTGCACAATTG TTGGAACGGCTT GGTCTGTTGAGT AAGGACCGTTTC CGCCTAAACCGT TGTGAATTCGGA CGGCCTAAGTTC TCCTAGGTCCGA CTCGTCGACTGA AAGTAGGAAGGA AACACCATCGAC CATTCGTGGCGT AGCGCTCACATC TCCTCACTATCA TCTTTCATACCG CGTGCCGCTTAA CTATAGACACGA TACTACGTGGCC TGGTTATGGCAC GCCTGCAGTACT CATTCCCGAAAG GCGTCATGCATC CAAGAGCGGATG GGCCAGTTCCTA CGAGGTTCTGAT GCCCAAGTTCAC TTGTCAGCTGGA CGTTGGACAAAT CCTTTGGCTGAG GATGTTCGCTAG AACTCCTGTGGA ATAAAGAGGAGG ATCTGCGCACCA TTGTTGATGGAG CGACCCATACGT CTATCTCCTGTC TAATGGTCGTAG GCGCCGAATCTT CCACGTACGTAA CTTACACTGCTT CTGGATTACGGT ACTCACAGGAAT TTGCACCGTCGA ATCCCAGCATGC ACGATATGGTCA AATGCGCGTATA ACCACACGTAGT ATGATGAGCCTC TGCTACAGACGT GCTTCCAGACAA GAGACAGTGGAA TGCCATTAGAGC CTAGTGACCTAG GTCGACAGAGGA ATGGCCTGACTA ACACAGTCCTGA TCGTAGTAATGG CGAAGGGTTGGA GGATTCGTGTCC TGTCGCAAATAG ACGCACATACAA ATTATACGGCGC AGGCTGTACTCC GAGCAACATCCT GTGAGATACCTA CATCCCTCTACT TGAGTGGTCTGT ATTCAGATGGCA CGGAAGAGAACA TCGTGTTGTGGC CGCGGTTACTAA TATACCGCTGCG GATAGCACTCGT TAAACGCGACTC CTGCGGATATAC ATTTCGACCCGG AGGCCCGTTTAC AGTTGAGGCATT TAGCGCGAACTT CCTCGGGTACTA CTAGCGTGCGTT TGGATTGTGAAC TGTTGTTGGGAA ACAATAGACACC CATACACGCACC TTCACCTGTATC ACCATGTAGAAC CCGTTGGACTAC CTGAATCTGGTG CGGTCAATTGAC ACCTCAGTCAAG CTCCAGGTCATG TAGCTCACAGCA TCTGGCTACGAC GGCCTCACTGAT GTGGAGTCTCAT TCGACCAAACAC CAGGATTCGTAC GTCTTGGGTCGT TCAGGCGTAAAT GTGGTTCGATGT GCTCGAAGATTC CCACCCAGTAAC CGCATACGACCT CTGTATGGAGCT TCACGGTGACAT TCGAGAGTTTGC AGGCTTACGTGT ATATCGCGATGA GCCTCGTACTGA ATGCAACTCGAA CAAGGTCACCTC TACGACTCTGGC TCTCTACCACTC CGCCGGTAATCT ACCAACAGATTG CTAACTGACGCA CTATACGCGAAC GCGTAACTCTCG ACTTCCAACTTC CCGATGCCTTGA GTGGCCTACTAC AACGTCCTGTGC GAGGAGTAAAGC CTTTCCCTTCGA CTCACCTAGGAA AGCAGGCACGAA TTCCCTTCTCCG AGACGACGTGGA GCAGCATGTTAA AAGATTTGCAGC GTGTTGTCGTGC TACGCAGCACTA CATTTGACGACG AAGGTTCCGATA GTTGGGATCCTC AACGGCTGGAAG CCACAGATCGAT CGCTTAGTGCTG AAGTGAAGCGAG AGTTTCTGGTGG TTCAGCGATGGT ATCGTCCGCGAT TATCGACACAAG CAAAGTTTGCGA TGCCGCCGTAAT TTCCTCCTGCTA ACAATCCCGAGT TCACAGACAATG GATTCCGGCTCA TCGAGCCGATCT AACCTCGGATAA CATCTCAGTCGG GTTCTTGGAGAC GAGACTATATGC CGTAATTGCCGC CTCATCATGTTC GTGCTTGTGTAG ATATGCGAGACT TAGCCCTGATGC AGAGGGTGATCG GGTGACTAGTTC CCAGGGACTTCT CAACTAGACTCG GACCACTGCTGT TTGTCCCAAGCG TAGAGAATGCTC ATGGGTTCCGTC GCAATCCTTGCG AGTGCCCTTGGT ATAGACACTCCG TTCGTACTTCGT AGAGCATCCACT TAGGCATGCTTG CCTGCTTCCTTC GGAACGACGTGA GAATCGCCGATT CTGCTCAGGCAT ACAGTCTGCATG AACTAGTTCAGG CAAGGCACAAGG TGTCAGCTGTCG TAGAAGGCTCCT GACATCTGACAC AATCGGTCCGAT ATTCTGCCGAAG GGCCTATAAGTC CTGGTGCTGAAT CGACTAACTAGA CACAACCACAAC CCGTTCAATGGA AGCATGTCCCGT TCCATTTCATGC GACAGAGGTGCA TACAACCGAGTA GCACCAATCTGC CTCTCGGCGTAA GTACGATATGAC TCGGCGATCATC TCAGACCAACTG CTCATGGTAGCA ATTAGCAGCGTA TCCCTCTGAGAG GTGGTGGTTTCC GTTTCACGCGAA AGTGATGTGACT AACGACACGCTT TCCGATAATCGG AAGTTAGTCCGC TAGTATGCGCAA ACAAGAACCTTG CTTAGCTACTCT CCTGGCTGAATA CTTTCAGGACCG TCAGATACCAGC TGCGCTGAATGT TACTCTCTTAGC TCGGTCCATAGC TTCGGATGTGAA CGTCCTACAGTG TCGAAGACGTAT ATGGCTGTCAGT AACTGTTCGCGC CACGTTTATTCC CTAGGTCCGACT GTAACTCAACAG CACTTCTTTGTG GTTCTCTTCTCG CGAAGCATCTAC GAAACGGAAACG AGATCCCGTACC CGTGGAAGACGA CGTCGATTGCAC CGTAAGATGCCT GTTTGGCCACAC GGTCGTGTCTTG TCTGGTGCATCG GAGAGGGATCAC GTTGCCTCTGAG GCGTTCTAGCTG TCAGGTTGCCCA CGTCGTCTAAGA CAGCTGGTTCAA TCGGCTTGGAAT CACCTCCAAGGT GTTGTTCTGGGA TCATTCCACTCA CAAGCGTTGTCC GCTGGATTGTCA TGAACAGGTTCA GTAAGCCTCGAT GGACTTCCAGCT GTCACATCACGA GACTTATGCCCG TCTTGTTTCTGG GAGAGATCGACG CTCCGCTATAGG CTCACAACCGTG CGACATTTCTCT GTGACGTTAGTC TTGAACAAGCCA ATACAAACGCAC ACTGCTATCGCG CTGCTATTCCTC GGACGTTAACTA GAGTCTTGGTAA CCAGGTTAATGC GATTCACTGTGG ACCACTTGCCAG ATGTCACCGCTG TAGCAGTTGCGT TCGTCGCCAAAC ATTCGTACCTCT GCTTGCCAATCG ACCAGAAATGTC TGTAACGCCGAT CACGCTATTGGA AACATGCATGCC TAGCGTTCCAGA CTGACACGAATA ATGCTTGCTCTT AGCAGAACATCT AACTTCACTTCC GTCTGTTGAGTG CCAGAAGTGTTC GTTCTAAGGTGA ACAGTTGTACGC TGGAGTAGGTGG CCAGTGGATATA TGAGTTCGGTCC ACGATCATCTGG CGTGAATCAACC AGCTACTGCGTC TTGGCTCTATTC TGTGTGTAACGC TTACGTGGCGAT ACTGTACATGAG GAGCTAAGTTAC ACTGCCCGATAC GATCCCACGTAC CCAATCGTGCAA CAATGCCTCACG TGCCCGGACTTA AGCGATTCCTCG CACAGCGTCCTA TACCGCTTCTTC AGGCTAGCAGAG TGTACGGATAAC ATCCCGTACGTG CCAACCCAGATC ACGTCCACTGTG TGTGCGATAACA GTCACTCCGAAC AATCAACTAGGC CTTGTTGTTCTG GATTGCTACCAG CGCTAATCGTGA GATTATCGACGA CACCGAAATCTG GTGAGGGCAAGT TGACAGAATCCA GGCTCTAACGTA GGCCGTTCGATT GCCTAGCCCAAT TGACGTAGAACT CGTGGGCTCATT CACTGTATGAAG AATCTGCACCGA GGAACTTACTCG GATGTATGTGGT CTATGCCGGCTA CGTACCAGATCC TGGATGCGCATT CCAGCCTTCAGA CAGTTACCCAAG ACTCCTTGTGTT GTGGTATGGGAG ATGTTTAGACGG GCCCATATCAGA CCGTGTTAGACA GAGGGACGCAAT GTCACGGACATT TGTACCAACCGA ACATGTCACGTG CGTGTGTGCTCA ACCTCTATTCGT TAGGCCATGTAA GCGAGCGAAGTA AGGGTACAGGGT CTTTAGCGCTGG ATCCATGAGCGT GGCAAGGCACAA AACCGTCGCCTA ATCTACCGAAGC AGAGTGCTAATC CTGGTCTTACGG TAGACTTCAGAG GCCATTATAGAG TTACGAAGTTGG ACTTGGTGTAAG TTGGCGGGTTAT CAAGTCGAATAC TGATTCCCGGTG TAACCGAACCAC AGATAGCTCGCT TCTTGGAGGTCA CACGATGGTCAT GCAAGTGTGAGG AGTTCCACGGCT GGTGCGTCACTT CTGGTTGGCATC TCACCTCCTTGT GTCACCAATCCG CTCGGTCAACCA GGAAGCTTAACT TGTGCTTGTAGG CTGCTTCTTACA GCACACCTGATA CACTAACAAACG ACCCTATTGCGG GGAGACGTTCTT TGACTCTGCGGT GTTCGAGTGAAT GCGACAATTACA TTCCAGGCAGAT TCCGTTCGTTTA ATTGCGCTACCG GTACACTGATAG TTCTTCTACCGC TCATGCTCCATT TATGGTACCCAG ACCACCGTAACC CCGACCAGCTTA TTACATCCCTTG TCTCTCGATCAT AGCTGTCAAGCT CACGACTTGACA CATTTCGCACTT CAATCCACCGAA GGTGTGAGAAAG AATCCATGACAG GAGAGCAACAGA CTTGGAGGCTTA TTAAGCGCCTGA TACGCGTACAGT CTCTTTGTCGAT GGTATTCAAAGC TACTCGGGAACT ACGTGGTTCCAC TGCGGGATTCAT CCGTCAAGATGT GTGAACTGGATT GGTCCACCTAAC CGTGCTTAGGCT GACGCTTTGCTG CAAACTGCGTTG TACACGCTGATG CCTAACGGTCCA TGATCACTCTTC TACCGAAGGTAT ACAGGGTTTGTA TTAGACTCGGAA CGTTTCAAGGAC TGTAGCCGCTTG GGCACGAAAGGT CACTCATCATTC GCCTATGAGATC GACCGATAGGGA GCAGAACTTAGT TACCCGACTAAG CATGAGACTGTA GTATTTCGGACG CAAACCTATGGC GGCGAACTGAAG ACCCGTTGATGA CGTAGTACCACA GGTCATCACGAT TATCTATCCTGC ATCGCTTAAGGC CGGCACTATCAC GACGTAGAACGG CGGAGAGACATG AGTCTAGAGTAC TTGCCAAGAGTC ACCATCCAACGA AGGTGGTGGAGT CGGTACCTACCA CCAAAGCCAGTT TGCGCAAAGGAG AGTAGCGGAAGA GCAATAGGAGGA ATTCCCAGAACG GCGTTTGCTAGC TACGATGAGTTG GGTTTGCACATG GCAATTAGGTAC CCGAACGTCACT AGACGTTGCTAC AGAAACAGCTCT GCTTGGTAGGTT TGGGTTAACACA CATACCGTGAGT ACACCAACACCA AGAATAGCGCTT CTCAGACTCAGA CCGGAATCCATA TAGGTTGCTTGG ATGTGTGTAGAC CCATCACATAGG AAGCGTACATTG CCGAGTACAATC ATCGGCTTCCGA CAGGAACCAGGA CCTGCGAAGTAT CGACACGGAGAA GTTATGACGGAT GATATGAACTGC CACTAGACCCAC TGCTCGATGTGC TTCTCTCGACAT GAACCTATGACA AGCCTCATGATG GCAGTCTAAGAT GGAAAGGAGAAT AGGTTTGGCTTG GCTCTCCGTAGA ATGCCGGTAATA GTGTATCGCCAC CGGCGCATTATA GAGTATCTGAGT TACTCCAGGCTG GTTAAGCTGACC GAACAGCTCTAC CCAAACTCGTCG GGTGCTAATCAC CTCGCTAGATAG TTCGGCATAGTG ATGCCATGCCGT GTGAGTCATACC ACGTGAGGAACG CGTTTGGAATGA CCAGGACAGGAA GTGCCATAATCG GACATTGTCACG TGGCCGTTACTG TGAATCGAAGCT GGTTAGAGCGGA AAGGGTTAGTCT TGCAGATCCAAC GCCAACAACCAT TAGAGCTGCCAT CTGCAGTAAGTA GTAGTAGACCAT GTGACTAGTGAT TCACTCTTGTAC ATCAGTACTAGG ATCTAGTGGCAA TATAGGCTCCGC ATCAAGATACGC GGCCTTCAGTCA TGGTGGAGTTTC TCCTCGAGCGAT CCTTCAATGGGA ATCGTGTGTTGG TCTATCTGGCTT ACACGTTTGGGT AGAACACGGAAG ACCCAAGCGTTA TTGACGACATCG CTTCCGCAGACA GGAAACAAACGG CGAACGTCTATG TCGAAACATGCA TGCAGCAAGATT ACATACTGAGCA GCACTATACGCA GATTGGCATAGT TCATGTGAACGA AACTAAGGACTC AGCAACATTGCA GGCTAAACTATG TCTGGGCATTGA GAGTTGTACGAT TCTCCGTTCCCT AACTCAATAGCG GATGTGGTGTTA AAGAGCAGAGCC CCAATGATAAGC CTCGAAATGCAA CTGATTACGAGA CTTAGAACGTGC CAGAAATGTGTC GGAGAGATCACG TTAAACCGCGCC AGAAGAAAGGCA TCTGAATGGTAG CCGTATATGCGC GTAGAGGTAGAG TCAACCCGTGAA CTTGCATACCGG CCACTCTCTCTA CATCGTTGGTCG TATGACGTACGA CGTGATCCGCTA GTTTGAAACACG GTGCACGATAAT CCTCCTAATTCA TAGATCCTCGGA TCTCTGAACAGG GGTTATTTGGCG AGAGAGACAGGT GGTCTAGGTCTA TTCATGGCCAGC TCGGACAGTGTT CCTTTATAGTCC GGATCGTAATAC TCGCCAGTGCAT TCAGGACGTATC ATTGGACACGCT TGATGTGCTAAG TGTAGGTGTGCT GCATAGCATCAA GCTCAGGACTCT GAAAGGTGAGAA AATTCACCTCCT CAGTAAATCGCA TCCCACGAAACA GTGTTAGATGTG CACTTTGGGTGC GAATATACCTGG ATGAAGCACTGT CAAGTTTCCGCG TACGCTACGACC TTAGAGCCATGC TCTAGCCTGGCA GTCGCTTGCACA TTGATGTGAGGT ACATCGTTGACG GTCAGTATGGCT TGAACCCTATGG AATGCAATGCGT TCTACCACGAAG TCTTGCGGAGTC ACGAAAGAGCAG CCATATCCCGGA AGAGTCTTGCCA CGAATGAGTCAT AATATCGGGATC TTAGTCGTGACG TGATGAACCCGT TCGTACCAGGAT ACAACACTCCGA CAACGCTAGAAT TAGTGCATTCGG TGCCAGACCACT GCTCTTATGCTT AGTGACTGTCAA CGATGCTGTTGA ATCAGAGCCCAT TCAATGACCGCA AGGCTCCATGTA CGACCTCGCATA GGTGAGCAAGCA ACGACTGCATAA TCTGTAGAGCCA CTATCGGAAGAT ACTACTGAGGAT CTAATTCTCTGC AGTTCATACGGC ACGCGAACTAAT CCGACTCTAGGT CGGATTGCTGTA TATCTGGAAGTG GGAAGTGGCCAA TCGCTTTAACCT AGCTATGTATGG ATCCTACGAGCA GGTACTGTACCA CAGCTATGGACT GATAATGTGCAC GGCTTACTTGGA ACGGGTCATCAT GACAACGAATCT ATCGAATCGAGT TTGCTGGACGCT CTCTGAGGTAAC CCATCCGCAACA GAAACATCCCAC TGCGGTTGACTC CTAGCAGTATGA CTACTAGCGGTA ATTTGCTTTGCC CGCAATGAGGGA CGTACTCTCGAG TGAGAAGAAAGG GTTAATGGCAGT TACAGGACGGGA TACTGGTAAGAC GCTACAAGCCCT TCAGTTCTCGTT TCGGATCTGTGA GTATGGAGCTAT CTCAGGAGACTT TTGAGAAGCACT ATTGAAGTCTGG TCGTGCGTGTTG GCCGGTACTCTA CCTTCTGTATAC TCGTTGGGACTA ATAACGGTGTAC GGATTACGCTGT GTTATCGCATGG CACAGGATTACC ACGCTGTCGGTT GTCCATGGTTCG TCCCGTAGCATG CAGCAGTCTTCG GATCACGAGAGG CGATATCAGTAG CTCGTTTCAGTT TGGCATGTTGGT CAGATGTCGCTA CGTAGCCAACAT GTAAATTCAGGC CATAAGGGAGGC GCGAACCTATAC AATCGTAAGGTC TGAGCAACATAC ATACAGCATACG AGTGTTTCGGAC TGTGTTACTCCT CTCTCATATGCT CTTACGAGTAGA GGTTCATGAACA CTGAGTGAGTAT ACACGCGGTTTA GGTACCTGCAAT CCAGTATCGCGT CAACTGTCAGAC GAGCGAGTTAGG GCTTGTACCGAC TGGCAAATCTAG TCGCCTATAAGG TCGTTTCTTCAG TGACTGCGTTAG GCTCAATCAGAA CGCTAGGATGTT CACCTTACCTTA AGTGGCACTATC AGTACCTAAGTG GGCTGATGTCAT GACCATGTAGTA GGACAAGTGCGA TTAACCTTCCTG TAACCCGATAGA GGATGCAGGATG TGTCCAGTTCGG CACACGCCTGAT GTTCGTATACGG TGCCGTATGCCA GTGTGCTAACGT CCACTTGAGAGT ACTCGTGATAGC TCTTCGCAGCAG CGGGTAGGGTAA CGTGACAATAGT CTTGCGGCAATC GCACTTCATTTC GCCCTCAAATGC TCTCATGTGGAG ATGCGCCCGTAT CGCTACAACTCG TGAGGTTTGATG AGAATCCACCAC TAAATCACGCGC TTCCATCATGTC CTGTCGTGTCAG TTAAGACAGTCG ATTGCTGGTCGA CTCAAGTCAAAG GGCGTGCATTAT GTCCTACACAGC ACGGTGAAAGCG TCTGCACTGAGC AAGAAGCCGGAC GTACCTAGCCTG GGTCAATATTGG GAGGTGGGAGTT TCACGTATTCTC CGCAGATTAGTA ACGGGATACAGG CACTGAGTACGT AGGTTCTTAGGC TGGCCTAGTCAA GAAGGTGAAGGT TGGGTCCCACAT AAGAGTCTCTAG TCAAGCAATACG TAGGTGCAATCA TCCTTCCCTGCT CACATGGGTTTG CACTGGTGCATA TCCGTCATGGGT CATGTTGGAACA GTCCAAAGCGTT CTCACTGCTTCT TAGGTAACCGAT AACGTAGGCTCT AGATCTATGCAG ATGGGACCTTCA AGATCGTGCCTA TAGGAGAGACAG GGTCGAATTGCT AGTTGTAGTCCG GCACAAGGCAAG GCTATTCCTCAT CTCCTCCCTTAC TGTTCCTCTCAC TGTAAACAGGTC TCGTCAAACCCG CGGCAAACACTT GTCTCTGAAAGA GAGCATTACATG GCGTTAACCCAA GTTACGTGGTTG TAATCGGTGCCA GCGAGTTCCTGT GTTCTGCTTGTT AAGCACGTCTCA CCACACGTTTGG AGGATCAGGGAA TTGATCCGGTAG TTCCGAATCGGC GTCAAGACCTCA TAGGGAGACCGA ACAGCATAGCTC TAGGACGGGAGT CGGGTGTTTGCT TACCTAGTGAGA TTGTTACGTTCC ATAAGCCCAATG AATGTGGCTCAC GCAACGAACGAG TTGACCGCGGTT CGTTCTGGTGGT CAGTTCGAGATA ACGTGCCTTAGA GAGTTCCATTGG TGACGGTTTAGC GTGCAACCAATC TTGGTCTCCTCT AATGTCACCAGA TCCTGCTATCTA TCTGATCGAGGT AAGTGTGGTTGT GCTTGAGCTTGA CTGCATACTGAG CAGCCTGCAAAT CACGAAAGCAGG CAAGTGAAGGGA CTTCGTTTCGTA CGCTGTGGATTA CAGGGCCTTTGT TTGCAAGTACCG TCAAGTCCGCAC TGCCCATCAGGT CACCGCTCACAA CTGTCAGTGACC CGATGAATATCG GCTTCTCTCACT TAGCACCTAAAG AGGTTGCTGTAA CTGAACAGTTGC ACGATTCGAGTC GTCAATTAGTGG CGAGATAGTTTG GTTTCTTGTTGC TAAGTACTGCAG CGCTCTTAACGG GGTTCGGTCCAT AGTACGCAGTCT CGCGTCAAACTA ACCTAAAGCTGC GCCGATTGTAAC GGAGTCTCTTGC CTGATCCATCTT AGCAGCTATTGC TTGACACACGAC ACCACGATGCTA CGGTGGAAGCAA AAGTTCCGGCCT TATGTGCCGGCT CTCGGATAGATC ATAAGGTCGCCT GCATCTAAAGCC GTTGAAGCACCT GCGCTGTTTAAG TGGTCGCATCGT TTCCCGAAACGA TTGCCCTTTGAT CGTTGACACCCA TGTCTTTACCTG GACAATTCCGAA TGTAAGACTTGG GAACTTTAGCGC CCTGGAATTAAG CTTGGGTTAGGT CCTTGTTCACCT AGGTCTCCCGAT CGGATCTAGTGT TCCTTAGAAGGC TGAGACCCTACA CTACGTGAAATG CAACCACTCGGT ACGATGGTTGAT CGATCTTCGAGC GATGGACTTCAA AAGTATCCTGCG GCCAGCTTCATG TCTTAGTCGGGC AGACTTCTCAGG GTCGAATTTGCG TACTGAGCCTCG CAAATGGTCGTC GTGCATTCGCCA GTACCGTTGCAA GGATGTCTTCGC GCATCAGAGTTA AGAAGGCCTTAT ACACATAAGTCG TGAGAGTCCCTC CTGATAGCACAC TCCTGAACACAG GTGGTCATCGTA TGGAGCCTTGTC TACTGCCAGTGA CTCTGTAGCCGA ACAGGTAGAGAG AAGCCTCTACGA CTGAAGGGCGAA CTCGATGTAAGC GAGTTTACGGTC GCAGTAACTGTC TGCTCACGTGTG TACTTGCCACGG CGCTCACAGAAT AGCTTCGACAGT GGCACACCCTTA CATATAGCCCGA GTAATAATGCCG GCATAAACGACT ATTCGGTAGTGC ATACGCATCAAG GTCCAGCTATGA CAGTGCACGTCT CTCGGCACCAAT CTTTGCACTTTG CGAGCTGTTACC AGATGTCCGTCA TCGCGCAACTGT CAAGACTGACCT ACTCGAAACCAA TGACACGACATC CAACACATGCTG GCACCTGTTGAA ATTCCTCTCCAC CCGATAAAGGTT ACCGTAAGACAT TGTTGACGATGC ATTCTCTCACGT CCTAGAGAAACT TGGTTCATCCTT CTTTGTCAGGGC ATCACGGGAGAG GACAAGAAGGTG CGACTCTAAACG GAGGTTCTTGAC AGCACTTTGAGA TCCGAAGACAAT TCACTGCTAGGA GAGTGCTCTAAC GTCTTCAGCAAG CTGTAAAGGTTG CCACGGTACTTG ACTTCGGATGCA CTAATCAGAGTG TTGTGTCTCCCT CGGATAACCTCC TGAGTCATTGAG ACTAGTTGGACC TAACATCAGGCA TTGGCATTGGCA CGTTACCGGACT AGGGTGACTTTA TACGGCAGTTCA GATCAACCCACA TAATGAGATGCC TATAATCCGAGG TGTGCACGCCAT GACTTCATGCGA CTCTAGAAGAGT ATGCGAGACTTC ATCGGTGGAATT TCCAGATAGCGT TCCCAGAAGCTC GCCTGTCTGCAA TGCACAGTCGCT CGCTTGTGTAGC TATAGTGGGCCT AATCCGGTCACC ACGCTAGATTGA ACTGATGGCCTC CATGCGGATCCT ATGAATGCGTCC TCGACGGAGAGA AAGTGCTTGGTA TTACGGCTGGTC TTCGATGCCGCA TGCTCCGTAGAA GACTCTGCTCAG ATCTGACATCGG GGTAAAGGGTCG TGCAATGGTACC TGTGGCTCGTGT TGATAGGTACAC CACGTACACGTA GATAGGGCCAAG GCTTTCTCAATC AACAGGTCTCTG AACTTTCAGGAG CGAGTTCATCGA CAGAGCTAATTG CGGGCTTCATCA ACAGTGCGTCCT GTGCTAATAGGT TGCACGTGATAA AAGCAGATTGTC TTATCCAGTCCT CGTAACGTAATG TAGGAACTCACC GCGATCACACCT GTTCGGTGTCCA TAGAGGCGTAGG CTAAGACGTCGT TAGCGACCTCAC TGTATTGGACAG AATGGACCGTTC AAGACAGCTATC TCAGCGCCGTTA GGCTCAGATTCC ACCCTGGGTATC AGAAAGGGTGTG GTACGTCACTGA ATTGACCGGTCA TAGACCGACTCC CTTGGTAGTGCC AGCGAGAAGTGA GCTCACAATGTG TAGCCTGTCGTG TTCTCCATCACA GTCAACGCTGTC GTGCTGCGCTTA CTTCAAGATGGA TATTGCAGCAGC ACAGACGACGGA CGTAGGTAGAGG ACAGGAGGGTGT AGTAGGAGGCAC GCTGCGTATACC AGATTCGCTCGA TCTATGCGAACG ATTTAGGACGAC GCTGTCGTCAAC ACCCGGATTTCG ACAAGGCAAGGC AGCCGGAGAGTA CTATGAGTCCAG GGATAGCCAAGG ATAGAGGCCATT CGTCCGTATGAA CGTTAGTGACTG CCTGTAGGTTGC AGTCCTTTATCC TGGTTGGTTACG AAGCTTGAAACC CGATTAGGAATC GCCGTTGATGCT AAGGCCTTTACG AGTTTGCGAGAT GTCGTCCAAATG TAAGCGTCTCGA ACGTCTCAGTGC TTCAACCTTTCG CTAGGCAATCAA TCAACGTGCTGC CAACGTGCTCCA ATAGCTTCGTGG TAGTAGCACCTG TGGGAGGTGGTA AGGACCTCGTTC GAACCAGTACTC TACACAAGTCGC CGGGATCAAATT AGGTCATCTTGG CGCCTGCCAATA CTTGTCTGGAGC TGATAATGCACG GCGTCCATGAAT AGTCATCGAATG TGCTGTGACCAC TTGAGCTTGAGC ACCGCATCAATG TAGTGATGACCA GTAATGCGTAAC ATCTTGGAGTCG ACACTTCGGCAA TACTAACGCGGT AAGGTCAATCGT ACAGCCACCCAT GTCGCCGTACAT AGCACCGGTCTT ACCTCCCGGATA ATCCGCAGTCAC ACCTACTTGTCT TATGTTGACGGC GGAATCCGATTA GCAAATCAGCCT GAAGAGGGTTGA AGTGTACCATGA TGTTGGATCGTG CGAGTATACAAC CACCCGATGGTT GCAAGCTGTCTC AGTAGACTTACG CCGATTGAATCG ACTGGATCTCGC TACACCTTACCT TTCTGAGAGGTA AGCGGCCTATTA TGGAAACCATTG TATATGTGCGAG TCAAGGGACCTT CGTTCAAGCTAG ATCCCTACGGAA TCTTCAACTACC AGTCCGAGTTGT CACCCACGTTGA AAGTCGACACAT AACTCGCGCTAC GGTTCCATTAGG TGGAATTCGGCT CCGCGATTTCGA TAGTGGGTCAAT AACATTGCAGGT TACCAGGATTGC GTGTTCCCAGAA TAAGATGCAGTC ACACACCCTGAC CCTAAACTACGG CCATGAAGTGTA GGTTGTAAGTGT CCGAGGTATAAT TGCCGAGTAATC TCACGAGTCACA ACTCCCGTGTGA TCCACAGGGTTC CAACGAACCATC AGCGTAATTAGC ACCTTGACAAGA CACAAAGCGATT CTGCAAGCCTGT TCATTAGCGTGG CCATGCTTAGAG CTCGTGAATGAC GTAACCACCACC CACCGTGACACT CCAACAGCCAAT ATGTCGAATAGC AATGGCGACTAT AGGTGAGTTCTA CATAGCTCGGTC GAAGATCTATCG CGGTTCACATAG CTGACCGTTAAG GACAGGTTGTAT CCTGTCCTATCT AACCATGCCAAC GACGGAACAGAC TCAACAGTAGTG TCGGGCTCTTAG GACTATAATGGC GGTTTAACACGC TATGGAGCTAGT GGACCGCTTTCA AACACATGGGTT ACTTTAAGGGTG TTCAGGAACTAG AGACAGTAGGAG ACTACCTCTTCA CACGGTCCTATG ATCGTAGTGGTC TGGACCACTAGT CAACAGGTAACT GCCACGACTTAC GATGATAACCCA GAATGACGTTTG CGAGTCACGATT AACCAGCAGATT TAGTTGAGCTGA ATTGTTCCTACC GGCCCAATATAA ACTTACGCCACG AGTGCGTTCTAG ATCGAGGATCTA GTCTCAAAGCAC GCCGTAAACTTG TTGTATGACAGG ACGCCTTTCTTA TTCTTAACGCCT TAGCTGGCGTTC AGTTGCCTGAAC GCAGATTTCCAG GGTAAGTTTGAC TTGGTGCCTGTG ACCCAGTATGGT CACAAGTATCGA TGGTAGTCTGAA AGATGATCAGTC CTACCACGGTAC CATCGGATCTGA CGTTAAGTCAGC GATTGTGCAACC GCATGTCGAAAT GAGACGTGTTCT CGGTCTGTCTGA CATGTCTTCCAT TCACAACACCGC CTACAGGGTCTC CCTATGCACGGT TATCACCGGCAC GTACATGTCGCC GTTACAGTTGGC AGCAAGGTCTTC GTACCAGGTACT GCGTGGTCATTA TATGCCAGAGAT TTCTAGAGTGCG CGGACTCGTTAC TCTAAACCCTCT GTATACCCTTCT AGTCACATCCGC AGGTCCAAATCA ACGGATGTTATG TCTCGCACTGGA CCTGATCACACG TAGGTCTAGGTC AGCGTCTGAACT ACCGTGCTCACA TTGAGGCTACAA TTCTGGTCTTGT AAGCTGCCTAGT GACAGTAGCTTC ATCGCGACTGCT CTCCCTTTGTGT GTAGGAACCGGA GTCCACTTGGAC ATTTGTGGGTAG TGAACGTTGGAT TGGAGGTTCTCA AGCTGCACCTAA ACATCTAGCAGA GATTTAGAGGCT TACATGGAGCAT AGTGTGAACGTT TGCTTGTAGGCA CCTTGACCGATG CCGACATTGTAG GTCAGCCGTTAA GCCTCAGCAGTT ATGGTCACAAAC CTTAAATGGGCA CTATCATCCTCA CATGTAAGGCTC ACGGTTTCTGGA CATCTTCTGATC ACATAGCGGTTC GGTATCACCCTG ACTCTAGCCGGT TGCAAGCTAAGT GCAGCCATATTG CAGGTTGTGCCT GCTGTTTGACCG CGCCTTGATAAG CGATAGGCCTTA GTGTGTGCCATA ATAGGTGTGCTA GGTTGCCCTGTA CGAATACTGACA CGTTTATCCGTT AATGACCTCGTG TGACAACCGAAT ACCTAGCTAGTG TGGTTTCGAAGA TATCCTGGTTTC TTGTACTCACTC CTTAGGCATGTG TAGGCTCGTGCT GTCCTGACACTG TGCGTTCTAGCG CATTGTCCCTAT TTCCCACCCATT CCAGATATAGCA CTCCTTAAGGCG GGACTCAACTAA AGTCCACTGGTA ACCGACGCTTGT GCCGCATTCGAT GAGAGTCCACTT TTGCCTGGGTCA ATACGGGTTCGT GAACTCGCTATG CTGTGATCGGAT GAACGGGACGTA CAATTCTGCTTC CCTTTCACCTGT GGTAGTTCATAG ATGTACACCGGT ACGTGTAGGCTT ACTGGCAAACCT ATCAGCCAGCTC AGGATGGGATGC TAAGCTAAACCG GGTCTCCTACAG AATCAGAGCTTG GCTCCACAACGT CAGTGATACTGC CATTGGGAGTTC ACTGACTTAAGG CAATGTAGACAC AAGGAGTGCGCA GAGGATACTACT GATCGGTTAATG GATGCTGCCGTT TGGCGATACGTT AGGGAAAGGATC GCATCGTCTGGT CAGCGACTGTTA TTCCTAGGCCAG GCCTTACGATAG ACGACGCATTTG TATGGGTAGCTA GAGCCCAAAGAG ATTAAGCCTGGA TACCTGTGTCTT CGTCACTCCAAG AGGTATTACCGA CGATCACCACAA TGGCTTTCTATC AACGAGGCAACG TTACACAAAGGC TGTCAAAGTGAC CTAGAGCTCCCA ACAGCTCAAACA GAAGACAGCGAC GTATAGTCCGTG GTAACGGCTCTA GAACGCAATTCC GAGCGTATCCAT ACACCTGCGATC TCGTAAGCCGTC GTGTACATAACG ATCCGTCTGACG ATGGGCGAATGG GGCGTTGCATTC TGACGCCTCCAA TGCTGCTCAACG TGAAATGTCCCG GATCTCTGGGTA ACTAGCGTTCAG TTCTCGGTTCTC CGGATGCAAGAG ATTCGCCAAGAA CATCATACGGGT TTGCGACAAAGT GCTACTGGTATG TGACATTCACGG TACGTGATCCCG TACGGATTATGG TGCGAGTATATG GAATCCTCACCG CACATATTGGGC TGGGTAGATCTC ATAGCGAACTCA TACCACAACGAA CCTGACACACAC TTCAATAGGGAC AGCAATCGGTAT TAACGCTGTGTG TCTGGAACGGTT CAGCGTTTAGCC ATAGCCGATGTC GTTGGACGAAGG AACCAAACTCGA GTACTACCTCGG GGTATGGCTACT ATGCGTAATGCA ACACTATGAAGC GCCGTCTCGTAA TTCCTGTTAACC ACAATGTCACAG ACTCCGATAGAC ACGGAAATCCCT CTGGGTATCTCG CTATCCAAGTGG GCCATAGTGTGT GCTGAGCCTTTG GGTTTCTATCCT GACTACCCGTTG CAGTCTAGTACG GGTCCCGAAATT AACAGAGAGAGC ACGCAATGTCTG GCGTTGCAAACT GTGTCCGGATTC TCTGCGAGTCTG AATTCCGAACGC TCGGTTACGCTG AACCGCATAAGT TGTGGTGATGTA ATGTAGGCTTAG TTAGTACGCAGA AAGCCATTGAAC ACCTTACACCTT CTTTCGTTCAAC TGCTTCCAATTC GAATCTGACAAC CGATTGTTCCGG GTAGGTGCTTAC CCGAAGATTCTG GCCGAGATAATT CACACTGAAGTC CCTAAGAGCATC CGCATTTGGATG GTTGGCGTTACA TCGAGTATCGAA ACTATCAGTGGC GATGGTTTCAGC ATAACATGTGCG GAAGTAGCGAGC GCCCTATCTTCT AGACTCAGACTC TAATTGCAGAGC CTTGAGAAATCG TTGCGGACCCTA AGGTACGCAATT GACCTTTCAAGG TACCGGCTTGCA CTACACAGCACA GCGGAAACATGG GTCCCTATTATC CAAGCAGGTGAG AGTCGGCATCTC GAAATGCTACGT AACGTTAGTGTG TGGGACATATCC GGAGAACGACAC ATATACCTGCGG TCTGAGGTTGCC TGCATGACAGTC GAACGATCATGT CAGCTTCGACTG TGTCTGACGCAA GATCATTCTCTC TCAATCGCTTTC TTCAGACCAGCC ATCTTTCCCTGA CATATCCAGCCG AGACATACCGTA CTACCGATTGCG ACGCATCGCACT CTCCGAACAACA TCTCACTGTTCC GATCCTCATGCG TCACCCAAGGTA CAGTAGCGATAT GGTCACACATCA GCTATGGAACTC ATTATCGTCCCT AGCCAGTCATAC GGATACTCGCAT AGAACTTGACGT CTCCACATTCCT CCAGACCGCTAT TAACGGCGCTCT CTAAGTTGCAAG CTTGAACCCGAC TACGTTTGGCGA AGCTCTAGAAAC GTTTGCTCGAGA CGCGATATCGTC GACGTGTCCATC AATCGCCCTTGG TCCATCGACGTG CAAACGCACTAA CTGATGTACACG AGAGCCAAGAGC CGGCGATGAAAG CGATGTGTGGTT GAACAAAGAGCG AGGCATCTGCTC TGGGAATGTTGT CCGCTACGTGAT GCGAAGTTGGGA GCTAAGTGATGT AGACCTGACCCT CAATCATAGGTG CTGGTAAGTCCA GCATTCGGCGTT AAGGGACAAGTG CATCGACGAGTT ATAAGTAACCGC AGAGCTCCTCTG CGCCATTGTGCA AGTGTCGATTCG GGAGTTGAGGTG GACTTGGTAAAC GACAAACCTTGC TCCAACTGCAGA CTATTAAGCGGC AGCATCCCTAAG AATCACGGTGCT CATTAGCTGGAA TAAAGACCCGTA CCTACCATTGTT CAGACGAGGAAC ACGACCTACGCT CCACAACGATCA TGTATCTTCACC GAGTCCGTTGCT TCGCTACAGATG GATGTCATAGCC CCGGTGTGATTC GACTGACTCGTC GATAACTGTACG TCGGTGTACCAA TGTTGCGTTTCT ATAGTGTTCGGC TCGTGGATAGCT TAAACCTGGACA AACACGGTTTGA GCATACTACAGC TAATCTCGCCGG GACGCACTAACT CCGAATTGACAA CTTGTGCGACAA GAGGTATTCTGA CAGATCCCAACC GGCGATTTACGT CTGGCATCTAGC AGAGTAAGCCGG ATGTTCCTCATC AGAGATTATGCC TAAGGCATCGCT GGTGGTCGTTCT AGACACCAATGT CGGTATAGCAAT TGAATACCTGGC ACCCATACAGCC ACTATGGGCTAA AATACGTCAAGC CTTGGCCTGTAG CTCCCACTAGAG CGCACTACGCAT GCATTGAGTTCG ATGGCAATTCAG ATCAAACGCATG AGCCCTGCTACA CAGTCGTTAAGA GTTGCTGAGTCC CAGTGTCATGAA CGGTCCTGAGTT CCTTATAGAAGG CTACGAAAGCCT CTATGGTGAACC CGGTGACCTACT CTCGAGCGTACT GGCCAAGGAAGT ATAATTGCCGAG GGACCAAGGGAT ACATCCCTACTT TTAAGGACTGAC CCTCTACTCTAA GGCATGTTATCG GTATTGGTCAGA TGAAGCACACTA GTGGAAGAGACA GAGTCGATCTTG AGGCACAGTAGG AGAACCGTCATA GTGAATGTTCGA TAACTAGGACGT GACCTACCGCAT CTACTTACATCC AACTGGAACCCT AGTCGCTACACA GAAAGAGTCTCT ATGTAATAGGCC CTCTTCTGATCA ATACTCGGCTGC AACCACTAACCG TCACCGGAATCC GACTCGCAACTA ATGCTAACCACG ACGCTTAACGAC TTCGCTAACCTT CGACTGCAGCTT CTGACGATCCGT ACCAATCTCGGC AGCTTACCGACC GACACTCACCGT GTTACCCGAGCT GTGCGAGGACAA TATCCAAGCGCA AGGGCTATAGTT TCAGAGTAGACT CCTAGGTCCCAA GCAGAGAGGCTA GTACTGAAGATC TGTCTCGCAAGC GACCAAATGTCC TTGAGTGGTCTG TCCTTGTCCTTG TCGCCGTGTACA CAGCCGCATATC GATGCAACTTCG CGACGAGATTAT CTACAATTGAGG AACTGCGATATG GATACGTTCGCA CACCACAGAATC AGTACTGCCTGC GTTGACCATCGC CTTCCAACTCAT CCAAGATTCGCC GGAGCTCTGTAT GAAGTCCACACT CAATGAGGGAGA GAGATCGCCTAT GAGGCTGATTTA CCTTAAGGGCAT GTAGAATGCTCC AAGCAACGGTGG TGTACATCGCCG GAGTTAGCATCA GCTGCTACAAGT ACACCCTATCGG CTCCAATGACGC TGTTAAGCAGCA TGTAGTATAGGC GTAAACGACTTG AGGAGGATAAAG ATGGAAGGTGGC ACGGCGTTATGT CTCACGCAATGC CGCCCTCTTCTT GCATGGGTTATC CCGGCTTATGTG ACTTTGCTTTGC GTCCCGTGAAAT ACTAGACGACTA GTTCCCAACGGT CTGTGCAACGTC CAAAGCGGTATT GGACAGTGTATT AGGTTAAGTGCT GTCAGAGTATTG AGTCAATGGCCT CGAAACTACGTA ACACGACTATAG ATATCCTGGGAC ATGACAGAACCT GGAACACATGTT GAGGACCAGCAA GTGTAGGTGCTT TTGTAGCCGACA ACAAGTGCTGCT AGCGCATATCCA AATAGCATGTCG TGAACTAGCGTC TCAGAAGCTCAA AATAGTCGTGAC TGCAACTTGCAG CGGAGTAATCCT TCCGAGTCACCA ACTGTGACGTCC TACAAGTGGTCC GTGTGGCAGAAG CTGTGTCCATGG TCCTCTTTGGTC TTGCAGTGCAAC GCTGGTCTAGTC GTGACCCTGTCA CTTCGCGGATGT TCCACCCTCTAT TGTCATGGCTGA GGCATCCTGGTT CACGCAGTCTAC ATAGGCTGTAGT TCGTGACGCTAA TTCGTGAGGATA GTGCCTCAGGTT TTCACTGTGCGG TGTGTAGCCATG ACGGCTAGTTCC TCCCAACCTAGG ATTACAGCGACA AACGAATACCAC AAGGGCGCTGAA GCACTGGCATAT TAGAATCAACGC ATGCAGAGATCT ATGGTTCACCCG GTTTCCGTGGTG GGCATTAGTTGA CACAATACACCG CGTATGCCGTAC TAGCGGAAGACG AGGAACCAGACG CGGTAGTTGATC GTATGACTAGCA AGCCGACTCTGT CCTCATGCTATT TAATGCCCAGGT TGAAAGCGGCGA ATGCTCTAGAGA CTATTCTTGGCT CCATCTTACCAT TATGAACGTCCG GGTTACGGTTAC AGCTAGCGTTCA TCGGTAGCAACT TATGCTCTCTCA CCACATTGGGTC ACATCAGGTCAC GGTCTTAGCACC CCAAATGATGAC CGTGTAGTAGAT TCAGTCAGATGA GTTGATACGATG TACCATCCATCT GCAGGTAACATT ACATGGGCGGAA AAGTCACACACA CAGACACTTCCG AGGGATGGACCA GCACGTTCTACG CCGCTGATGTCA GCTGTGATTCGA TCACCATCCGAG ACTAATACGCGA GACTGGAGATGG ACGAGTTTACCG CTAGCTATGGAC ACCCACCACTAG TCATACAGCCAG ACTAAGTACCCG GGAGATTGGAGA CTTGACGAGGTT CAGAAGGTGTGG GGAGGCCATAAG TAAGTGAGTACC AAGCCCAGCATT ACCTGGGAATAT GAAGCTTGAATC GTCCGATCCTAG ATCGACAACACC GGTGAAACCTAT CTCTGCCTAATT ACTAGGATCAGT CTGTGGGATTCA AGCACACTACAC TGGTAAGAGTCT ATATGACCCAGC GCTCCTTAGAAG TTGTCTACCTAC GAATGTTGCGCT GCGCTTAGAATA CTCTATTCCACC TCCCATTCCCAT GAAGGCTCCTTA CGCGCAAGTATT AGGTGTATCACC ATTGAGTGAGTC TGGCGTCATTCG AGATTACAACCG ATAGTTAGGGCT ATTGTCAAGCAG TTATGGTACGGA AATCCTCGGAGT TCTTCTGCCCTA GTTCAACAGCTG TTCGCAGATACG GCTAGTTATGGA CTGGACGCATTA TGAAGTCACAGT TCAGCAAATGGT CATAGGCCATCA CAGATTAACCAG ACCGATTAGGTA CTTAGTGCAGAA AGGGACTTCAAT CCTTGGAATCGC GGCTGCATACTC ATGTGCTGCTCG CATCAGTACGCC GAAGTGTATCTG CACTTGCTCTCT TTGGTAAAGTGC TACGTACGAAAC TAGAACACCATG TCCTGTGCGAGT GCAACTTCGGTA AAGTGGCTATCC ATCACATTCTCC CCGCATGACCTA CCAACGTAACCA GCCAATCCAACA AACCGATGTACC AGCCTGGTACCT GAGAATGGAAAG AAGGTGGACAAG CTGGAACATTAG TCGATTGGCCGT GCTAAAGTCGTA AACCCTAACTGG CAATTGCGTGCA TTAGCCCAGCGT GCATTACTGGAC TCTCAGCGCGTA TCCATACCGGAA ACCAGCTCAGAT AATGGTTCAGCA TTGGGCCACATA GACCCTAGACCT GTTCAGACTAGC ACGGTACCCTAC CAGCAAGAGGAC CACACAAAGTCA TATTCAGCGGAC GACACCACAATA TCATAGGGTAGT CTAGTACAAGCC GCCAAGGATAGG GTTCCGGATTAG CGATTTAGGCCA ATGGAGTTGTTG AGAGCGGAACAA CGCCACGTGTAT GCGTGTAATTAG AGGATATTCGTG CGTATCTCAGGA GCAGTTGCCTCA GCAACCGATTGT CTGTAGCTTGGC CAATACGACCGT TAGTTCGGTGAC CGCGCCTTAAAC CATGTGCTTAGG ATGCCTCGTAAG GCCATGTGTGTA CCATGGCTGTGT TCCGCGCAAGTT GTTCCTCCATTA ACCTATGGTGAA GACTCCTAGACC CTAGTCGCTGGT TAACCACCAACG ACCTGTCCTTTC CTGTTACAGCGA AAGGCAAGAAGA TCCAAGCGTCAC TGCGTCAGCTAC GTTCACGCCCAA CAGTCAGGCCTT ACGAGGAGTCGA GCTTCATTTCTG CGAAATGCATGT CGATCGAACACT ACTGAGCTGCAT GCGGTACTACTA AACTTGGCCGTA ATGATCGGTACA CATGCCAACATG ACGAAGTCTACC TCAGCTGACTAG CATACGATACAG TTACCCGCACAG GAGTACAGTCTA ACCGTCTTTCTC ACCTGATCCGCA GGTTGAGAAGAG CCTGTTAGCGAA CCTACATGAGAC AGTCTGTCTGCG CAAGCTAGCTGT CTGGGAGTTGTT GCTCCGACCATA TCCGTGGTATAG CCGCACTCAAGT GTGGATAAACTC ATCATCTCGGCG ACAAATCGTTGG TCTACGGCACGT TGTGGAAACTCC GGTACAATGATC ATTACCCACAGG GAAGGAAAGTAG ATGCTGCAACAC TTAGGCAGGTTC ACTGTCGCAGTA CACATCAGCGCT ACAAACATGGTC TTCTCATGGAGG TAAGACTACTGG CATCCTGAGCAA TGACCATAGTGA GGACTATCGTTG CATAGTGATTGG CGCGAAGTTTCA CAACATCGTAGC GATAAGCGCCTT GCTATATCCAGG GCTATCAAGACA CGATACACTGCC GGCAATCATCTG TAGTCTAAGGGT TATTCCCACGTT CCGTGACAACTC TTGAAATCCCGG TATCGCGCGATA AATTAGGCGTGT CCATTAGTTCCT CGTTCCTTGTTA GTTAGGGAGCGA TACGGTCTGGAT TGCTCTTGCTCT TAACCTTCGCTT GGAATTATCGGT TTACTGTGGCCG TCGTTCAGGACC TCCACTAGAGCA GTAATCTGCCGA CATCAAGCATAG ATATAAGGCCCA TGATCCGGGTAT CATTGCAAAGCA GGTGGCATGGAA

TABLE 2 5′ universal forward primer binding sequence barcode sequence 3′ universal reverse primer binding site site fragment fragment fragment sequence fragment fragment (SEQ ID NO: 1) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 2) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 3) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 4) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 5) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 6) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 7) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 8) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 9) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 10) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 11) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 12) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 13) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 14) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 15) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 16) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 17) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 18) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 19) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 20) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 21) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 22) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 23) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 24) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 25) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 26) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 27) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 28) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 29) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 30) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 31) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 32) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 33) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 34) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 35) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 36) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 37) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 38) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 39) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 40) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 41) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 42) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 43) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 44) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 45) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 46) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 47) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 48) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 49) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 50) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 51) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 52) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 53) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 54) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 55) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 56) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 57) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 58) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 59) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 60) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 61) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 62) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 63) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 64) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 65) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 66) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 67) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 68) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 69) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 70) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 71) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 72) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 73) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 74) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 75) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 76) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 77) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 78) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 79) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 80) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 81) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 82) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 83) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 84) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 85) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 86) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 87) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 88) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 89) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 90) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 91) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 92) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 93) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 94) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 95) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 96) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 97) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 98) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 99) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 100) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 101) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 102) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 103) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 104) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 105) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 106) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 107) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 108) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 109) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 110) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 111) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 112) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 113) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 114) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 115) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 116) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 117) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 118) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 119) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 120) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 121) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 122) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 123) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 124) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 125) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 126) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 127) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 128) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 129) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 130) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 131) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 132) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 133) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 134) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 135) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 136) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 137) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 138) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 139) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 140) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 141) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 142) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 143) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 144) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 145) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 146) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 147) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 148) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 149) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 150) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 1S1) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 152) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 153) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 154) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 155) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 156) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 157) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 158) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 159) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 160) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 161) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 162) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 163) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 164) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 165) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 166) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 167) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 168) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 169) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 170) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 171) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 172) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 173) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 174) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 175) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 176) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 177) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 178) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 179) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 180) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 181) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 182) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 183) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 184) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 185) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 186) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 187) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 188) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 189) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 190) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 191) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 192) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 193) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 194) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 195) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 196) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 197) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 198) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 199) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 200) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 201) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 202) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 203) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 204) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 205) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 206) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 207) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 208) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 209) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 210) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 211) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 212) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 213) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 214) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 215) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 216) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 217) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 218) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 219) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 220) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 221) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 222) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 223) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 224) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 225) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 226) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 227) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 228) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 229) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 230) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 231) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 232) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 233) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 234) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 235) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 236) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 237) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 238) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 239) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 240) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 241) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 242) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 243) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 244) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 245) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 246) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 247) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 248) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 249) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 250) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 251) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 252) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 253) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 254) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 255) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 256) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 257) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 258) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 259) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 260) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 261) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 262) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 263) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 264) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 265) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 266) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 267) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 268) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 269) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 270) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 271) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 272) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 273) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 274) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 275) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 276) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 277) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 278) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 279) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 280) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 281) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 282) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 283) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 284) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 285) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 286) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 287) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 288) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 289) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 290) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 291) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 292) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 293) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 294) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 295) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 296) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 297) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 298) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 299) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 300) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 301) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 302) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 303) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 304) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 305) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 306) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 307) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 308) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 309) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 310) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 311) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 312) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 313) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 314) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 315) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 316) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 317) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 318) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 319) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 320) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 321) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 322) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 323) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 324) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 325) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 326) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 327) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 328) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 329) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 330) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 331) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 332) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 333) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 334) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 33S) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 336) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 337) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 338) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 339) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 340) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 341) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 342) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 343) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 344) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 345) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 346) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 347) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 348) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 349) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 350) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 351) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 352) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 353) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 354) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 355) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 356) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 357) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 358) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 359) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 360) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 361) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 362) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 363) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 364) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 365) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 366) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 367) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 368) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 369) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 370) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 371) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 372) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 373) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 374) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 375) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 376) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 377) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 378) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 379) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 380) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 381) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 382) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 383) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC (SEQ ID NO: 384) CCTACGGGAGGCATCAG GCAGATCTCG CCTACGGGAGGCATCAG AGTCAGTCAGCC GGATTAGATACCCTAGTAGTC

In one illustrative aspect, the control composition for qPCR comprises a nucleic acid construct comprising at least one barcode sequence fragment linked at its 5′ or 3′ end to primer binding site fragments. In another embodiment, the nucleic acid construct comprises at least one universal sequence fragment. In another embodiment, the nucleic acid construct comprises at least a first and a second universal sequence fragment, and the first universal sequence fragment can be linked to the 5′ end of the barcode sequence fragment and the second universal sequence fragment can be linked to the 3′ end of the barcode sequence fragment. In one aspect, the universal sequence fragments can be extended as needed to make the nucleic acid construct longer for different applications.

In various embodiments, the universal sequence fragments can be from about 10 base pairs in length to about 270 base pairs in length, from about 10 base pairs in length to about 260 base pairs in length, from about 10 base pairs in length to about 250 base pairs in length, from about 10 base pairs in length to about 240 base pairs in length, from about 10 base pairs in length to about 230 base pairs in length, from about 10 base pairs in length to about 220 base pairs in length, from about 10 base pairs in length to about 210 base pairs in length, from about 10 base pairs in length to about 200 base pairs in length, from about 10 base pairs in length to about 190 base pairs in length, from about 10 base pairs in length to about 180 base pairs in length, from about 10 base pairs in length to about 170 base pairs in length, from about 10 base pairs in length to about 160 base pairs in length, from about 10 base pairs in length to about 150 base pairs in length, from about 10 base pairs in length to about 140 base pairs in length, from about 10 base pairs in length to about 130 base pairs in length, from about 10 base pairs in length to about 120 base pairs in length, from about 10 base pairs in length to about 110 base pairs in length, from about 10 base pairs in length to about 100 base pairs in length, from about 10 base pairs in length to about 90 base pairs in length, from about 10 base pairs in length to about 80 base pairs in length, from about 10 base pairs in length to about 70 base pairs in length, from about 10 base pairs in length to about 60 base pairs in length, from about 10 base pairs in length to about 50 base pairs in length, from about 10 base pairs in length to about 40 base pairs in length, from about 10 base pairs in length to about 30 base pairs in length, from about 10 base pairs in length to about 20 base pairs in length, from about 10 base pairs in length to about 15 base pairs in length, from about 8 base pairs in length to about 15 base pairs in length, or from about 8 base pairs in length to about 12 base pairs in length.

First and second primer binding site fragments are included in the nucleic acid construct. In this aspect, the primers can be any primers of interest. In one embodiment, the first primer binding site fragment is linked at its 3′-end to the 5′ end of a first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of a second universal sequence fragment (see FIG. 1 for an example). In various embodiments, the primer binding site fragments can range in length from about 15 base pairs to about 28 base pairs, from about 15 base pairs to about 26 base pairs, from about 15 base pairs to about 24 base pairs, from about 15 base pairs to about 22 base pairs, from about 15 base pairs to about 20 base pairs, from about 16 base pairs to about 22 base pairs, from about 16 base pairs to about 20 base pairs, from about 17 base pairs to about 20 base pairs, or can be about 18 base pairs.

In all of the various embodiments described above, the entire nucleic acid construct, not including plasmid sequence if a plasmid is present, can range in length from about 80 base pairs to about 300 base pairs, from about 80 base pairs to about 290 base pairs, from about 80 base pairs to about 280 base pairs, from about 80 base pairs to about 270 base pairs, from about 80 base pairs to about 260 base pairs, from about 80 base pairs to about 250 base pairs, from about 80 base pairs to about 240 base pairs, from about 80 base pairs to about 230 base pairs, from about 80 base pairs to about 220 base pairs, from about 80 base pairs to about 210 base pairs, from about 80 base pairs to about 200 base pairs, from about 80 base pairs to about 190 base pairs, from about 80 base pairs to about 180 base pairs, from about 80 base pairs to about 170 base pairs, or from about 80 base pairs to about 160 base pairs.

Various embodiments of the nucleic acid constructs, including the forward and reverse primer binding site fragments, 5′ and 3′ universal sequence fragments, and the barcode sequence fragment are shown in Table 2 above having SEQ ID NOS:1 to 384. The corresponding full sequences are also shown as SEQ ID NOS:385 to 768 in Table 3 below. These embodiments have primer binding site fragments in accordance with the nucleic acid construct exemplified in FIG. 1 .

TABLE 3 full sequence (SEQ ID NO: 385) CCTACGGGAGGCATCAGGCAGATCTCGTCCCTTGTCTCCACGAGACTGATTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 386) CCTACGGGAGGCATCAGGCAGATCTCGGCTGTACGGATTATCACCAGGTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 387) CCTACGGGAGGCATCAGGCAGATCTCGTGGTCAACGATACATCGCGTTGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 388) CCTACGGGAGGCATCAGGCAGATCTCGATCGCACAGTAAGCACATAGTCGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 389) CCTACGGGAGGCATCAGGCAGATCTCGGTCGTGTAGCCTGGCAAATACACTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 390) CCTACGGGAGGCATCAGGCAGATCTCGAGCGGAGGTTAGGTCATGCTCCAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 391) CCTACGGGAGGCATCAGGCAGATCTCGATCCTTTGGTTCCCTAGTAAGCTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 392) CCTACGGGAGGCATCAGGCAGATCTCGTACAGCGCATACTTACCGACGAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 393) CCTACGGGAGGCATCAGGCAGATCTCGACCGGTATGTACGCTTAGATGTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 394) CCTACGGGAGGCATCAGGCAGATCTCGAATTGTGTCGGAAAGACGTAGCGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 395) CCTACGGGAGGCATCAGGCAGATCTCGTGCATACACTGGTTACCTTACACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 396) CCTACGGGAGGCATCAGGCAGATCTCGAGTCGAACGAGGTGACTAATGGCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 397) CCTACGGGAGGCATCAGGCAGATCTCGACCAGTGACTCACTCTCTCACTTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 398) CCTACGGGAGGCATCAGGCAGATCTCGGAATACCAAGTCATTGCAAGCAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 399) CCTACGGGAGGCATCAGGCAGATCTCGGTAGATCGTGTACACGTGACATGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 400) CCTACGGGAGGCATCAGGCAGATCTCGTAACGTGTGTGCCACAGTTGAAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 401) CCTACGGGAGGCATCAGGCAGATCTCGCATTATGGCGTGCTAGGATCACTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 402) CCTACGGGAGGCATCAGGCAGATCTCGCCAATACGCCTGGATGACCCAAATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 403) CCTACGGGAGGCATCAGGCAGATCTCGGATCTGCGATCCACCGGAGTAGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 404) CCTACGGGAGGCATCAGGCAGATCTCGCAGCTCATCAGCTGAGGACTACCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 405) CCTACGGGAGGCATCAGGCAGATCTCGCAAACAACAGCTCAATCGGCTTGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 406) CCTACGGGAGGCATCAGGCAGATCTCGGCAACACCATCCAACACTCGATCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 407) CCTACGGGAGGCATCAGGCAGATCTCGGCGATATATCGCTGACCGGCTGTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 408) CCTACGGGAGGCATCAGGCAGATCTCGCGAGCAATCCTAGGAGGAGCAATAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 409) CCTACGGGAGGCATCAGGCAGATCTCGAGTCGTGCACATAGCGACGAAGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 410) CCTACGGGAGGCATCAGGCAGATCTCGGTATCTGCGCGTCTTCCCTAACTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 411) CCTACGGGAGGCATCAGGCAGATCTCGCGAGGGAAAGTCTGGAAGAACGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 412) CCTACGGGAGGCATCAGGCAGATCTCGCAAATTCGGGATGCTAGACACTACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 413) CCTACGGGAGGCATCAGGCAGATCTCGAGATTGACCAACTTGGATTGAACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 414) CCTACGGGAGGCATCAGGCAGATCTCGAGTTACGAGCTAGATATACCAGTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 415) CCTACGGGAGGCATCAGGCAGATCTCGGCATATGCACTGAACAAACTGCCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 406) CCTACGGGAGGCATCAGGCAGATCTCGCAACTCCCGTGAGTAGACATGTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 407) CCTACGGGAGGCATCAGGCAGATCTCGTTGCGTTAGCAGTACAGTTACGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 408) CCTACGGGAGGCATCAGGCAGATCTCGTACGAGCCCTAACAAGCCCTAGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 409) CCTACGGGAGGCATCAGGCAGATCTCGCACTACGCTAGATAGTGTCGGATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 410) CCTACGGGAGGCATCAGGCAGATCTCGTGCAGTCCTCGACTGAGCTCTGCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 421) CCTACGGGAGGCATCAGGCAGATCTCGACCATAGCTCCGCTTCGACTTTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 422) CCTACGGGAGGCATCAGGCAGATCTCGTCGACATCTCTTGTCATAAGAACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 423) CCTACGGGAGGCATCAGGCAGATCTCGGAACACTTTGGAGTCCGCAAGTTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 424) CCTACGGGAGGCATCAGGCAGATCTCGGAGCCATCTGTACGTAGAGCTCTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 425) CCTACGGGAGGCATCAGGCAGATCTCGTTGGGTACACGTCCTCTGAGAGCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 426) CCTACGGGAGGCATCAGGCAGATCTCGAAGGCGCTCCTTCCTCGATGCAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 427) CCTACGGGAGGCATCAGGCAGATCTCGTAATACGGATCGGCGGACTATTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 428) CCTACGGGAGGCATCAGGCAGATCTCGTCGGAATTAGACCGTGCACAATTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 429) CCTACGGGAGGCATCAGGCAGATCTCGTGTGAATTCGGACGGCCTAAGTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 430) CCTACGGGAGGCATCAGGCAGATCTCGCATTCGTGGCGTAGCGCTCACATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 431) CCTACGGGAGGCATCAGGCAGATCTCGTACTACGTGGCCTGGTTATGGCACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 432) CCTACGGGAGGCATCAGGCAGATCTCGGGCCAGTTCCTACGAGGTTCTGATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 433) CCTACGGGAGGCATCAGGCAGATCTCGGATGTTCGCTAGAACTCCTGTGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 434) CCTACGGGAGGCATCAGGCAGATCTCGCTATCTCCTGTCTAATGGTCGTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 435) CCTACGGGAGGCATCAGGCAGATCTCGACTCACAGGAATTTGCACCGTCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 436) CCTACGGGAGGCATCAGGCAGATCTCGATGATGAGCCTCTGCTACAGACGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 437) CCTACGGGAGGCATCAGGCAGATCTCGGTCGACAGAGGAATGGCCTGACTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 438) CCTACGGGAGGCATCAGGCAGATCTCGTGTCGCAAATAGACGCACATACAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 439) CCTACGGGAGGCATCAGGCAGATCTCGCATCCCTCTACTTGAGTGGTCTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 440) CCTACGGGAGGCATCAGGCAGATCTCGTATACCGCTGCGGATAGCACTCGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 441) CCTACGGGAGGCATCAGGCAGATCTCGAGTTGAGGCATTTAGCGCGAACTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 442) CCTACGGGAGGCATCAGGCAGATCTCGACAATAGACACCCATACACGCACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 443) CCTACGGGAGGCATCAGGCAGATCTCGCGGTCAATTGACACCTCAGTCAAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 444) CCTACGGGAGGCATCAGGCAGATCTCGGTGGAGTCTCATTCGACCAAACACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 445) CCTACGGGAGGCATCAGGCAGATCTCGGCTCGAAGATTCCCACCCAGTAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 446) CCTACGGGAGGCATCAGGCAGATCTCGAGGCTTACGTGTATATCGCGATGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 447) CCTACGGGAGGCATCAGGCAGATCTCGTCTCTACCACTCCGCCGGTAATCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 448) CCTACGGGAGGCATCAGGCAGATCTCGACTTCCAACTTCCCGATGCCTTGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 449) CCTACGGGAGGCATCAGGCAGATCTCGCTCACCTAGGAAAGCAGGCACGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 450) CCTACGGGAGGCATCAGGCAGATCTCGGTGTTGTCGTGCTACGCAGCACTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 451) CCTACGGGAGGCATCAGGCAGATCTCGCCACAGATCGATCGCTTAGTGCTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 452) CCTACGGGAGGCATCAGGCAGATCTCGTATCGACACAAGCAAAGTTTGCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 453) CCTACGGGAGGCATCAGGCAGATCTCGGATTCCGGCTCATCGAGCCGATCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 454) CCTACGGGAGGCATCAGGCAGATCTCGCGTAATTGCCGCCTCATCATGTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 455) CCTACGGGAGGCATCAGGCAGATCTCGGGTGACTAGTTCCCAGGGACTTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 456) CCTACGGGAGGCATCAGGCAGATCTCGATGGGTTCCGTCGCAATCCTTGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 457) CCTACGGGAGGCATCAGGCAGATCTCGTAGGCATGCTTGCCTGCTTCCTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 458) CCTACGGGAGGCATCAGGCAGATCTCGAACTAGTTCAGGCAAGGCACAAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 459) CCTACGGGAGGCATCAGGCAGATCTCGATTCTGCCGAAGGGCCTATAAGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 460) CCTACGGGAGGCATCAGGCAGATCTCGAGCATGTCCCGTTCCATTTCATGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 461) CCTACGGGAGGCATCAGGCAGATCTCGGTACGATATGACTCGGCGATCATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 462) CCTACGGGAGGCATCAGGCAGATCTCGGTGGTGGTTTCCGTTTCACGCGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 463) CCTACGGGAGGCATCAGGCAGATCTCGTAGTATGCGCAAACAAGAACCTTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 464) CCTACGGGAGGCATCAGGCAGATCTCGTGCGCTGAATGTTACTCTCTTAGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 465) CCTACGGGAGGCATCAGGCAGATCTCGATGGCTGTCAGTAACTGTTCGCGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 466) CCTACGGGAGGCATCAGGCAGATCTCGGTTCTCTTCTCGCGAAGCATCTACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 467) CCTACGGGAGGCATCAGGCAGATCTCGCGTAAGATGCCTGTTTGGCCACACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 468) CCTACGGGAGGCATCAGGCAGATCTCGGCGTTCTAGCTGTCAGGTTGCCCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 469) CCTACGGGAGGCATCAGGCAGATCTCGGTTGTTCTGGGATCATTCCACTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 470) CCTACGGGAGGCATCAGGCAGATCTCGGGACTTCCAGCTGTCACATCACGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 471) CCTACGGGAGGCATCAGGCAGATCTCGCTCACAACCGTGCGACATTTCTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 472) CCTACGGGAGGCATCAGGCAGATCTCGCTGCTATTCCTCGGACGTTAACTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 473) CCTACGGGAGGCATCAGGCAGATCTCGATGTCACCGCTGTAGCAGTTGCGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 474) CCTACGGGAGGCATCAGGCAGATCTCGTGTAACGCCGATCACGCTATTGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 475) CCTACGGGAGGCATCAGGCAGATCTCGAGCAGAACATCTAACTTCACTTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 476) CCTACGGGAGGCATCAGGCAGATCTCGTGGAGTAGGTGGCCAGTGGATATAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 477) CCTACGGGAGGCATCAGGCAGATCTCGTTGGCTCTATTCTGTGTGTAACGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 478) CCTACGGGAGGCATCAGGCAGATCTCGGATCCCACGTACCCAATCGTGCAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 479) CCTACGGGAGGCATCAGGCAGATCTCGTACCGCTTCTTCAGGCTAGCAGAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 480) CCTACGGGAGGCATCAGGCAGATCTCGTGTGCGATAACAGTCACTCCGAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 481) CCTACGGGAGGCATCAGGCAGATCTCGGATTATCGACGACACCGAAATCTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 482) CCTACGGGAGGCATCAGGCAGATCTCGGCCTAGCCCAATTGACGTAGAACTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 483) CCTACGGGAGGCATCAGGCAGATCTCGGATGTATGTGGTCTATGCCGGCTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 484) CCTACGGGAGGCATCAGGCAGATCTCGACTCCTTGTGTTGTGGTATGGGAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 485) CCTACGGGAGGCATCAGGCAGATCTCGGTCACGGACATTTGTACCAACCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 486) CCTACGGGAGGCATCAGGCAGATCTCGGCGAGCGAAGTAAGGGTACAGGGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 487) CCTACGGGAGGCATCAGGCAGATCTCGATCTACCGAAGCAGAGTGCTAATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 488) CCTACGGGAGGCATCAGGCAGATCTCGACTTGGTGTAAGTTGGCGGGTTATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 489) CCTACGGGAGGCATCAGGCAGATCTCGTCTTGGAGGTCACACGATGGTCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 490) CCTACGGGAGGCATCAGGCAGATCTCGTCACCTCCTTGTGTCACCAATCCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 491) CCTACGGGAGGCATCAGGCAGATCTCGGCACACCTGATACACTAACAAACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 492) CCTACGGGAGGCATCAGGCAGATCTCGGCGACAATTACATTCCAGGCAGATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 493) CCTACGGGAGGCATCAGGCAGATCTCGTCATGCTCCATTTATGGTACCCAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 494) CCTACGGGAGGCATCAGGCAGATCTCGAGCTGTCAAGCTCACGACTTGACAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 495) CCTACGGGAGGCATCAGGCAGATCTCGGAGAGCAACAGACTTGGAGGCTTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 496) CCTACGGGAGGCATCAGGCAGATCTCGTACTCGGGAACTACGTGGTTCCACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 497) CCTACGGGAGGCATCAGGCAGATCTCGCGTGCTTAGGCTGACGCTTTGCTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 498) CCTACGGGAGGCATCAGGCAGATCTCGTACCGAAGGTATACAGGGTTTGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 499) CCTACGGGAGGCATCAGGCAGATCTCGCACTCATCATTCGCCTATGAGATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 500) CCTACGGGAGGCATCAGGCAGATCTCGGTATTTCGGACGCAAACCTATGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 501) CCTACGGGAGGCATCAGGCAGATCTCGTATCTATCCTGCATCGCTTAAGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 502) CCTACGGGAGGCATCAGGCAGATCTCGTTGCCAAGAGTCACCATCCAACGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 503) CCTACGGGAGGCATCAGGCAGATCTCGAGTAGCGGAAGAGCAATAGGAGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 504) CCTACGGGAGGCATCAGGCAGATCTCGGCAATTAGGTACCCGAACGTCACTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 505) CCTACGGGAGGCATCAGGCAGATCTCGCATACCGTGAGTACACCAACACCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 506) CCTACGGGAGGCATCAGGCAGATCTCGATGTGTGTAGACCCATCACATAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 507) CCTACGGGAGGCATCAGGCAGATCTCGCCTGCGAAGTATCGACACGGAGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 508) CCTACGGGAGGCATCAGGCAGATCTCGTTCTCTCGACATGAACCTATGACAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 509) CCTACGGGAGGCATCAGGCAGATCTCGGCTCTCCGTAGAATGCCGGTAATAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 510) CCTACGGGAGGCATCAGGCAGATCTCGGTTAAGCTGACCGAACAGCTCTACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 511) CCTACGGGAGGCATCAGGCAGATCTCGATGCCATGCCGTGTGAGTCATACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 512) CCTACGGGAGGCATCAGGCAGATCTCGGACATTGTCACGTGGCCGTTACTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 513) CCTACGGGAGGCATCAGGCAGATCTCGGCCAACAACCATTAGAGCTGCCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 514) CCTACGGGAGGCATCAGGCAGATCTCGATCAGTACTAGGATCTAGTGGCAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 515) CCTACGGGAGGCATCAGGCAGATCTCGTCCTCGAGCGATCCTTCAATGGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 516) CCTACGGGAGGCATCAGGCAGATCTCGACCCAAGCGTTATTGACGACATCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 517) CCTACGGGAGGCATCAGGCAGATCTCGTGCAGCAAGATTACATACTGAGCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 518) CCTACGGGAGGCATCAGGCAGATCTCGAGCAACATTGCAGGCTAAACTATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 519) CCTACGGGAGGCATCAGGCAGATCTCGGATGTGGTGTTAAAGAGCAGAGCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 520) CCTACGGGAGGCATCAGGCAGATCTCGCAGAAATGTGTCGGAGAGATCACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 521) CCTACGGGAGGCATCAGGCAGATCTCGGTAGAGGTAGAGTCAACCCGTGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 522) CCTACGGGAGGCATCAGGCAGATCTCGCGTGATCCGCTAGTTTGAAACACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 523) CCTACGGGAGGCATCAGGCAGATCTCGGGTTATTTGGCGAGAGAGACAGGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 524) CCTACGGGAGGCATCAGGCAGATCTCGGGATCGTAATACTCGCCAGTGCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 525) CCTACGGGAGGCATCAGGCAGATCTCGGCATAGCATCAAGCTCAGGACTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 526) CCTACGGGAGGCATCAGGCAGATCTCGGTGTTAGATGTGCACTTTGGGTGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 527) CCTACGGGAGGCATCAGGCAGATCTCGTTAGAGCCATGCTCTAGCCTGGCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 528) CCTACGGGAGGCATCAGGCAGATCTCGTGAACCCTATGGAATGCAATGCGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 529) CCTACGGGAGGCATCAGGCAGATCTCGAGAGTCTTGCCACGAATGAGTCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 530) CCTACGGGAGGCATCAGGCAGATCTCGACAACACTCCGACAACGCTAGAATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 531) CCTACGGGAGGCATCAGGCAGATCTCGCGATGCTGTTGAATCAGAGCCCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 532) CCTACGGGAGGCATCAGGCAGATCTCGACGACTGCATAATCTGTAGAGCCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 533) CCTACGGGAGGCATCAGGCAGATCTCGACGCGAACTAATCCGACTCTAGGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 534) CCTACGGGAGGCATCAGGCAGATCTCGAGCTATGTATGGATCCTACGAGCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 535) CCTACGGGAGGCATCAGGCAGATCTCGACGGGTCATCATGACAACGAATCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 536) CCTACGGGAGGCATCAGGCAGATCTCGGAAACATCCCACTGCGGTTGACTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 537) CCTACGGGAGGCATCAGGCAGATCTCGCGTACTCTCGAGTGAGAAGAAAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 538) CCTACGGGAGGCATCAGGCAGATCTCGTCAGTTCTCGTTTCGGATCTGTGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 539) CCTACGGGAGGCATCAGGCAGATCTCGTCGTGCGTGTTGGCCGGTACTCTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 540) CCTACGGGAGGCATCAGGCAGATCTCGGTTATCGCATGGCACAGGATTACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 541) CCTACGGGAGGCATCAGGCAGATCTCGGATCACGAGAGGCGATATCAGTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 542) CCTACGGGAGGCATCAGGCAGATCTCGGTAAATTCAGGCCATAAGGGAGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 543) CCTACGGGAGGCATCAGGCAGATCTCGAGTGTTTCGGACTGTGTTACTCCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 544) CCTACGGGAGGCATCAGGCAGATCTCGACACGCGGTTTAGGTACCTGCAATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 545) CCTACGGGAGGCATCAGGCAGATCTCGTGGCAAATCTAGTCGCCTATAAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 546) CCTACGGGAGGCATCAGGCAGATCTCGCACCTTACCTTAAGTGGCACTATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 547) CCTACGGGAGGCATCAGGCAGATCTCGTTAACCTTCCTGTAACCCGATAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 548) CCTACGGGAGGCATCAGGCAGATCTCGTGCCGTATGCCAGTGTGCTAACGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 549) CCTACGGGAGGCATCAGGCAGATCTCGCGTGACAATAGTCTTGCGGCAATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 550) CCTACGGGAGGCATCAGGCAGATCTCGCGCTACAACTCGTGAGGTTTGATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 551) CCTACGGGAGGCATCAGGCAGATCTCGTTAAGACAGTCGATTGCTGGTCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 552) CCTACGGGAGGCATCAGGCAGATCTCGTCTGCACTGAGCAAGAAGCCGGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 553) CCTACGGGAGGCATCAGGCAGATCTCGCGCAGATTAGTAACGGGATACAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 554) CCTACGGGAGGCATCAGGCAGATCTCGTGGGTCCCACATAAGAGTCTCTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 555) CCTACGGGAGGCATCAGGCAGATCTCGCACTGGTGCATATCCGTCATGGGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 556) CCTACGGGAGGCATCAGGCAGATCTCGAACGTAGGCTCTAGATCTATGCAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 557) CCTACGGGAGGCATCAGGCAGATCTCGAGTTGTAGTCCGGCACAAGGCAAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 558) CCTACGGGAGGCATCAGGCAGATCTCGTCGTCAAACCCGCGGCAAACACTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 559) CCTACGGGAGGCATCAGGCAGATCTCGTAATCGGTGCCAGCGAGTTCCTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 560) CCTACGGGAGGCATCAGGCAGATCTCGTTGATCCGGTAGTTCCGAATCGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 561) CCTACGGGAGGCATCAGGCAGATCTCGCGGGTGTTTGCTTACCTAGTGAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 562) CCTACGGGAGGCATCAGGCAGATCTCGTTGACCGCGGTTCGTTCTGGTGGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 563) CCTACGGGAGGCATCAGGCAGATCTCGGTGCAACCAATCTTGGTCTCCTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 564) CCTACGGGAGGCATCAGGCAGATCTCGGCTTGAGCTTGACTGCATACTGAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 565) CCTACGGGAGGCATCAGGCAGATCTCGCGCTGTGGATTACAGGGCCTTTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 566) CCTACGGGAGGCATCAGGCAGATCTCGCTGTCAGTGACCCGATGAATATCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 567) CCTACGGGAGGCATCAGGCAGATCTCGACGATTCGAGTCGTCAATTAGTGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 568) CCTACGGGAGGCATCAGGCAGATCTCGGGTTCGGTCCATAGTACGCAGTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 569) CCTACGGGAGGCATCAGGCAGATCTCGCTGATCCATCTTAGCAGCTATTGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 570) CCTACGGGAGGCATCAGGCAGATCTCGTATGTGCCGGCTCTCGGATAGATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 571) CCTACGGGAGGCATCAGGCAGATCTCGTGGTCGCATCGTTTCCCGAAACGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 572) CCTACGGGAGGCATCAGGCAGATCTCGTGTAAGACTTGGGAACTTTAGCGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 573) CCTACGGGAGGCATCAGGCAGATCTCGCGGATCTAGTGTTCCTTAGAAGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 574) CCTACGGGAGGCATCAGGCAGATCTCGCGATCTTCGAGCGATGGACTTCAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 575) CCTACGGGAGGCATCAGGCAGATCTCGGTCGAATTTGCGTACTGAGCCTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 576) CCTACGGGAGGCATCAGGCAGATCTCGGCATCAGAGTTAAGAAGGCCTTATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 577) CCTACGGGAGGCATCAGGCAGATCTCGGTGGTCATCGTATGGAGCCTTGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 578) CCTACGGGAGGCATCAGGCAGATCTCGCTGAAGGGCGAACTCGATGTAAGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 579) CCTACGGGAGGCATCAGGCAGATCTCGCGCTCACAGAATAGCTTCGACAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 580) CCTACGGGAGGCATCAGGCAGATCTCGATTCGGTAGTGCATACGCATCAAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 581) CCTACGGGAGGCATCAGGCAGATCTCGCGAGCTGTTACCAGATGTCCGTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 582) CCTACGGGAGGCATCAGGCAGATCTCGCAACACATGCTGGCACCTGTTGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 583) CCTACGGGAGGCATCAGGCAGATCTCGATTCTCTCACGTCCTAGAGAAACTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 584) CCTACGGGAGGCATCAGGCAGATCTCGCGACTCTAAACGGAGGTTCTTGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 585) CCTACGGGAGGCATCAGGCAGATCTCGGTCTTCAGCAAGCTGTAAAGGTTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 586) CCTACGGGAGGCATCAGGCAGATCTCGCGGATAACCTCCTGAGTCATTGAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 587) CCTACGGGAGGCATCAGGCAGATCTCGAGGGTGACTTTATACGGCAGTTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 588) CCTACGGGAGGCATCAGGCAGATCTCGGACTTCATGCGACTCTAGAAGAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 589) CCTACGGGAGGCATCAGGCAGATCTCGGCCTGTCTGCAATGCACAGTCGCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 590) CCTACGGGAGGCATCAGGCAGATCTCGACTGATGGCCTCCATGCGGATCCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 591) CCTACGGGAGGCATCAGGCAGATCTCGTTCGATGCCGCATGCTCCGTAGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 592) CCTACGGGAGGCATCAGGCAGATCTCGTGTGGCTCGTGTTGATAGGTACACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 593) CCTACGGGAGGCATCAGGCAGATCTCGAACTTTCAGGAGCGAGTTCATCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 594) CCTACGGGAGGCATCAGGCAGATCTCGTGCACGTGATAAAAGCAGATTGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 595) CCTACGGGAGGCATCAGGCAGATCTCGGTTCGGTGTCCATAGAGGCGTAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 596) CCTACGGGAGGCATCAGGCAGATCTCGAAGACAGCTATCTCAGCGCCGTTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 597) CCTACGGGAGGCATCAGGCAGATCTCGATTGACCGGTCATAGACCGACTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 598) CCTACGGGAGGCATCAGGCAGATCTCGTTCTCCATCACAGTCAACGCTGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 599) CCTACGGGAGGCATCAGGCAGATCTCGCGTAGGTAGAGGACAGGAGGGTGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 600) CCTACGGGAGGCATCAGGCAGATCTCGATTTAGGACGACGCTGTCGTCAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 601) CCTACGGGAGGCATCAGGCAGATCTCGGGATAGCCAAGGATAGAGGCCATTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 602) CCTACGGGAGGCATCAGGCAGATCTCGTGGTTGGTTACGAAGCTTGAAACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 603) CCTACGGGAGGCATCAGGCAGATCTCGGTCGTCCAAATGTAAGCGTCTCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 604) CCTACGGGAGGCATCAGGCAGATCTCGCAACGTGCTCCAATAGCTTCGTGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 605) CCTACGGGAGGCATCAGGCAGATCTCGTACACAAGTCGCCGGGATCAAATTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 606) CCTACGGGAGGCATCAGGCAGATCTCGGCGTCCATGAATAGTCATCGAATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 607) CCTACGGGAGGCATCAGGCAGATCTCGGTAATGCGTAACATCTTGGAGTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 608) CCTACGGGAGGCATCAGGCAGATCTCGGTCGCCGTACATAGCACCGGTCTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 609) CCTACGGGAGGCATCAGGCAGATCTCGGGAATCCGATTAGCAAATCAGCCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 610) CCTACGGGAGGCATCAGGCAGATCTCGCACCCGATGGTTGCAAGCTGTCTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 611) CCTACGGGAGGCATCAGGCAGATCTCGTTCTGAGAGGTAAGCGGCCTATTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 612) CCTACGGGAGGCATCAGGCAGATCTCGATCCCTACGGAATCTTCAACTACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 613) CCTACGGGAGGCATCAGGCAGATCTCGGGTTCCATTAGGTGGAATTCGGCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 614) CCTACGGGAGGCATCAGGCAGATCTCGGTGTTCCCAGAATAAGATGCAGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 615) CCTACGGGAGGCATCAGGCAGATCTCGCCGAGGTATAATTGCCGAGTAATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 616) CCTACGGGAGGCATCAGGCAGATCTCGAGCGTAATTAGCACCTTGACAAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 617) CCTACGGGAGGCATCAGGCAGATCTCGCTCGTGAATGACGTAACCACCACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 618) CCTACGGGAGGCATCAGGCAGATCTCGAGGTGAGTTCTACATAGCTCGGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 619) CCTACGGGAGGCATCAGGCAGATCTCGCCTGTCCTATCTAACCATGCCAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 620) CCTACGGGAGGCATCAGGCAGATCTCGGGTTTAACACGCTATGGAGCTAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 621) CCTACGGGAGGCATCAGGCAGATCTCGAGACAGTAGGAGACTACCTCTTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 622) CCTACGGGAGGCATCAGGCAGATCTCGGCCACGACTTACGATGATAACCCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 623) CCTACGGGAGGCATCAGGCAGATCTCGATTGTTCCTACCGGCCCAATATAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 624) CCTACGGGAGGCATCAGGCAGATCTCGGCCGTAAACTTGTTGTATGACAGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 625) CCTACGGGAGGCATCAGGCAGATCTCGGCAGATTTCCAGGGTAAGTTTGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 626) CCTACGGGAGGCATCAGGCAGATCTCGAGATGATCAGTCCTACCACGGTACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 627) CCTACGGGAGGCATCAGGCAGATCTCGGAGACGTGTTCTCGGTCTGTCTGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 628) CCTACGGGAGGCATCAGGCAGATCTCGTATCACCGGCACGTACATGTCGCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 629) CCTACGGGAGGCATCAGGCAGATCTCGTATGCCAGAGATTTCTAGAGTGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 630) CCTACGGGAGGCATCAGGCAGATCTCGAGGTCCAAATCAACGGATGTTATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 631) CCTACGGGAGGCATCAGGCAGATCTCGACCGTGCTCACATTGAGGCTACAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 632) CCTACGGGAGGCATCAGGCAGATCTCGCTCCCTTTGTGTGTAGGAACCGGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 633) CCTACGGGAGGCATCAGGCAGATCTCGAGCTGCACCTAAACATCTAGCAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 634) CCTACGGGAGGCATCAGGCAGATCTCGCCTTGACCGATGCCGACATTGTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 635) CCTACGGGAGGCATCAGGCAGATCTCGCTATCATCCTCACATGTAAGGCTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 636) CCTACGGGAGGCATCAGGCAGATCTCGACTCTAGCCGGTTGCAAGCTAAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 637) CCTACGGGAGGCATCAGGCAGATCTCGCGATAGGCCTTAGTGTGTGCCATAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 638) CCTACGGGAGGCATCAGGCAGATCTCGAATGACCTCGTGTGACAACCGAATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 639) CCTACGGGAGGCATCAGGCAGATCTCGCTTAGGCATGTGTAGGCTCGTGCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 640) CCTACGGGAGGCATCAGGCAGATCTCGCCAGATATAGCACTCCTTAAGGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 641) CCTACGGGAGGCATCAGGCAGATCTCGGAGAGTCCACTTTTGCCTGGGTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 642) CCTACGGGAGGCATCAGGCAGATCTCGGAACGGGACGTACAATTCTGCTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 643) CCTACGGGAGGCATCAGGCAGATCTCGACGTGTAGGCTTACTGGCAAACCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 644) CCTACGGGAGGCATCAGGCAGATCTCGGGTCTCCTACAGAATCAGAGCTTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 645) CCTACGGGAGGCATCAGGCAGATCTCGACTGACTTAAGGCAATGTAGACACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 646) CCTACGGGAGGCATCAGGCAGATCTCGGATGCTGCCGTTTGGCGATACGTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 647) CCTACGGGAGGCATCAGGCAGATCTCGTTCCTAGGCCAGGCCTTACGATAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 648) CCTACGGGAGGCATCAGGCAGATCTCGATTAAGCCTGGATACCTGTGTCTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 649) CCTACGGGAGGCATCAGGCAGATCTCGTGGCTTTCTATCAACGAGGCAACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 650) CCTACGGGAGGCATCAGGCAGATCTCGACAGCTCAAACAGAAGACAGCGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 651) CCTACGGGAGGCATCAGGCAGATCTCGGAGCGTATCCATACACCTGCGATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 652) CCTACGGGAGGCATCAGGCAGATCTCGATGGGCGAATGGGGCGTTGCATTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 653) CCTACGGGAGGCATCAGGCAGATCTCGGATCTCTGGGTAACTAGCGTTCAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 654) CCTACGGGAGGCATCAGGCAGATCTCGCATCATACGGGTTTGCGACAAAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 655) CCTACGGGAGGCATCAGGCAGATCTCGTACGGATTATGGTGCGAGTATATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 656) CCTACGGGAGGCATCAGGCAGATCTCGATAGCGAACTCATACCACAACGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 657) CCTACGGGAGGCATCAGGCAGATCTCGTAACGCTGTGTGTCTGGAACGGTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 658) CCTACGGGAGGCATCAGGCAGATCTCGAACCAAACTCGAGTACTACCTCGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 659) CCTACGGGAGGCATCAGGCAGATCTCGGCCGTCTCGTAATTCCTGTTAACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 660) CCTACGGGAGGCATCAGGCAGATCTCGCTGGGTATCTCGCTATCCAAGTGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 661) CCTACGGGAGGCATCAGGCAGATCTCGGACTACCCGTTGCAGTCTAGTACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 662) CCTACGGGAGGCATCAGGCAGATCTCGGCGTTGCAAACTGTGTCCGGATTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 663) CCTACGGGAGGCATCAGGCAGATCTCGAACCGCATAAGTTGTGGTGATGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 664) CCTACGGGAGGCATCAGGCAGATCTCGACCTTACACCTTCTTTCGTTCAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 665) CCTACGGGAGGCATCAGGCAGATCTCGGTAGGTGCTTACCCGAAGATTCTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 666) CCTACGGGAGGCATCAGGCAGATCTCGCGCATTTGGATGGTTGGCGTTACAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 667) CCTACGGGAGGCATCAGGCAGATCTCGATAACATGTGCGGAAGTAGCGAGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 668) CCTACGGGAGGCATCAGGCAGATCTCGCTTGAGAAATCGTTGCGGACCCTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 669) CCTACGGGAGGCATCAGGCAGATCTCGCTACACAGCACAGCGGAAACATGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 670) CCTACGGGAGGCATCAGGCAGATCTCGGAAATGCTACGTAACGTTAGTGTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 671) CCTACGGGAGGCATCAGGCAGATCTCGTCTGAGGTTGCCTGCATGACAGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 672) CCTACGGGAGGCATCAGGCAGATCTCGGATCATTCTCTCTCAATCGCTTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 673) CCTACGGGAGGCATCAGGCAGATCTCGAGACATACCGTACTACCGATTGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 674) CCTACGGGAGGCATCAGGCAGATCTCGGATCCTCATGCGTCACCCAAGGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 675) CCTACGGGAGGCATCAGGCAGATCTCGATTATCGTCCCTAGCCAGTCATACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 676) CCTACGGGAGGCATCAGGCAGATCTCGCCAGACCGCTATTAACGGCGCTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 677) CCTACGGGAGGCATCAGGCAGATCTCGAGCTCTAGAAACGTTTGCTCGAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 678) CCTACGGGAGGCATCAGGCAGATCTCGTCCATCGACGTGCAAACGCACTAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 679) CCTACGGGAGGCATCAGGCAGATCTCGCGATGTGTGGTTGAACAAAGAGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 680) CCTACGGGAGGCATCAGGCAGATCTCGGCGAAGTTGGGAGCTAAGTGATGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 681) CCTACGGGAGGCATCAGGCAGATCTCGGCATTCGGCGTTAAGGGACAAGTGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 682) CCTACGGGAGGCATCAGGCAGATCTCGCGCCATTGTGCAAGTGTCGATTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 683) CCTACGGGAGGCATCAGGCAGATCTCGTCCAACTGCAGACTATTAAGCGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 684) CCTACGGGAGGCATCAGGCAGATCTCGTAAAGACCCGTACCTACCATTGTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 685) CCTACGGGAGGCATCAGGCAGATCTCGTGTATCTTCACCGAGTCCGTTGCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 686) CCTACGGGAGGCATCAGGCAGATCTCGGACTGACTCGTCGATAACTGTACGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 687) CCTACGGGAGGCATCAGGCAGATCTCGTCGTGGATAGCTTAAACCTGGACAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 688) CCTACGGGAGGCATCAGGCAGATCTCGGACGCACTAACTCCGAATrGACAAAGrCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 689) CCTACGGGAGGCATCAGGCAGATCTCGGGCGATTTACGTCTGGCATCTAGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 690) CCTACGGGAGGCATCAGGCAGATCTCGTAAGGCATCGCTGGTGGTCGTTCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 691) CCTACGGGAGGCATCAGGCAGATCTCGACCCATACAGCCACTATGGGCTAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 692) CCTACGGGAGGCATCAGGCAGATCTCGCGCACTACGCATGCATTGAGTTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 693) CCTACGGGAGGCATCAGGCAGATCTCGCAGTCGTTAAGAGTTGCTGAGTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 694) CCTACGGGAGGCATCAGGCAGATCTCGCTACGAAAGCCTCTATGGTGAACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 695) CCTACGGGAGGCATCAGGCAGATCTCGATAATTGCCGAGGGACCAAGGGATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 696) CCTACGGGAGGCATCAGGCAGATCTCGGGCATGTTATCGGTATTGGTCAGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 697) CCTACGGGAGGCATCAGGCAGATCTCGAGGCACAGTAGGAGAACCGTCATAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 698) CCTACGGGAGGCATCAGGCAGATCTCGCTACTTACATCCAACTGGAACCCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 699) CCTACGGGAGGCATCAGGCAGATCTCGCTCTTCTGATCAATACTCGGCTGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 700) CCTACGGGAGGCATCAGGCAGATCTCGATGCTAACCACGACGCTTAACGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 701) CCTACGGGAGGCATCAGGCAGATCTCGACCAATCTCGGCAGCTTACCGACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 702) CCTACGGGAGGCATCAGGCAGATCTCGTATCCAAGCGCAAGGGCTATAGTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 703) CCTACGGGAGGCATCAGGCAGATCTCGGTACTGAAGATCTGTCTCGCAAGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 704) CCTACGGGAGGCATCAGGCAGATCTCGTCGCCGTGTACACAGCCGCATATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 705) CCTACGGGAGGCATCAGGCAGATCTCGAACTGCGATATGGATACGTTCGCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 706) CCTACGGGAGGCATCAGGCAGATCTCGCTTCCAACTCATCCAAGATTCGCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 707) CCTACGGGAGGCATCAGGCAGATCTCGGAGATCGCCTATGAGGCTGATTTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 708) CCTACGGGAGGCATCAGGCAGATCTCGTGTACATCGCCGGAGTTAGCATCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 709) CCTACGGGAGGCATCAGGCAGATCTCGTGTTAAGCAGCATGTAGTATAGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 710) CCTACGGGAGGCATCAGGCAGATCTCGACGGCGTTATGTCTCACGCAATGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 711) CCTACGGGAGGCATCAGGCAGATCTCGACTTTGCTTTGCGTCCCGTGAAATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 712) CCTACGGGAGGCATCAGGCAGATCTCGCAAAGCGGTATTGGACAGTGTATTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 713) CCTACGGGAGGCATCAGGCAGATCTCGCGAAACTACGTAACACGACTATAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 714) CCTACGGGAGGCATCAGGCAGATCTCGGAGGACCAGCAAGTGTAGGTGCTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 715) CCTACGGGAGGCATCAGGCAGATCTCGAATAGCATGTCGTGAACTAGCGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 716) CCTACGGGAGGCATCAGGCAGATCTCGCGGAGTAATCCTTCCGAGTCACCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 717) CCTACGGGAGGCATCAGGCAGATCTCGCTGTGTCCATGGTCCTCTTTGGTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 718) CCTACGGGAGGCATCAGGCAGATCTCGCTTCGCGGATGTTCCACCCTCTATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 719) CCTACGGGAGGCATCAGGCAGATCTCGATAGGCTGTAGTTCGTGACGCTAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 720) CCTACGGGAGGCATCAGGCAGATCTCGTGTGTAGCCATGACGGCTAGTTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 721) CCTACGGGAGGCATCAGGCAGATCTCGAAGGGCGCTGAAGCACTGGCATATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 722) CCTACGGGAGGCATCAGGCAGATCTCGGTTTCCGTGGTGGGCATTAGTTGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 723) CCTACGGGAGGCATCAGGCAGATCTCGAGGAACCAGACGCGGTAGTTGATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 724) CCTACGGGAGGCATCAGGCAGATCTCGTAATGCCCAGGTTGAAAGCGGCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 725) CCTACGGGAGGCATCAGGCAGATCTCGTATGAACGTCCGGGTTACGGTTACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 726) CCTACGGGAGGCATCAGGCAGATCTCGCCACATTGGGTCACATCAGGTCACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 727) CCTACGGGAGGCATCAGGCAGATCTCGTCAGTCAGATGAGTTGATACGATGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 728) CCTACGGGAGGCATCAGGCAGATCTCGAAGTCACACACACAGACACTTCCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 729) CCTACGGGAGGCATCAGGCAGATCTCGGCTGTGATTCGATCACCATCCGAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 730) CCTACGGGAGGCATCAGGCAGATCTCGCTAGCTATGGACACCCACCACTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 731) CCTACGGGAGGCATCAGGCAGATCTCGCTTGACGAGGTTCAGAAGGTGTGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 732) CCTACGGGAGGCATCAGGCAGATCTCGACCTGGGAATATGAAGCTTGAATCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 733) CCTACGGGAGGCATCAGGCAGATCTCGCTCTGCCTAATTACTAGGATCAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 734) CCTACGGGAGGCATCAGGCAGATCTCGATATGACCCAGCGCTCCTTAGAAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 735) CCTACGGGAGGCATCAGGCAGATCTCGCTCTATTCCACCTCCCATTCCCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 736) CCTACGGGAGGCATCAGGCAGATCTCGATTGAGTGAGTCTGGCGTCATTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 737) CCTACGGGAGGCATCAGGCAGATCTCGTTATGGTACGGAAATCCTCGGAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 738) CCTACGGGAGGCATCAGGCAGATCTCGGCTAGTTATGGACTGGACGCATTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 739) CCTACGGGAGGCATCAGGCAGATCTCGCAGATTAACCAGACCGATTAGGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 740) CCTACGGGAGGCATCAGGCAGATCTCGGGCTGCATACTCATGTGCTGCTCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 741) CCTACGGGAGGCATCAGGCAGATCTCGTTGGTAAAGTGCTACGTACGAAACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 742) CCTACGGGAGGCATCAGGCAGATCTCGAAGTGGCTATCCATCACATTCTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 743) CCTACGGGAGGCATCAGGCAGATCTCGAACCGATGTACCAGCCTGGTACCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 744) CCTACGGGAGGCATCAGGCAGATCTCGTCGATTGGCCGTGCTAAAGTCGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 745) CCTACGGGAGGCATCAGGCAGATCTCGGCATTACTGGACTCTCAGCGCGTAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 746) CCTACGGGAGGCATCAGGCAGATCTCGTTGGGCCACATAGACCCTAGACCTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 747) CCTACGGGAGGCATCAGGCAGATCTCGCACACAAAGTCATATTCAGCGGACAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 748) CCTACGGGAGGCATCAGGCAGATCTCGGCCAAGGATAGGGTTCCGGATTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 749) CCTACGGGAGGCATCAGGCAGATCTCGCGCCACGTGTATGCGTGTAATTAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 750) CCTACGGGAGGCATCAGGCAGATCTCGGCAACCGATTGTCTGTAGCTTGGCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 751) CCTACGGGAGGCATCAGGCAGATCTCGCATGTGCTTAGGATGCCTCGTAAGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 752) CCTACGGGAGGCATCAGGCAGATCTCGGTTCCTCCATTAACCTATGGTGAAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 753) CCTACGGGAGGCATCAGGCAGATCTCGACCTGTCCTTTCCTGTTACAGCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 754) CCTACGGGAGGCATCAGGCAGATCTCGGTTCACGCCCAACAGTCAGGCCTTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 755) CCTACGGGAGGCATCAGGCAGATCTCGCGATCGAACACTACTGAGCTGCATAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 756) CCTACGGGAGGCATCAGGCAGATCTCGCATGCCAACATGACGAAGTCTACCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 757) CCTACGGGAGGCATCAGGCAGATCTCGGAGTACAGTCTAACCGTCTTTCTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 758) CCTACGGGAGGCATCAGGCAGATCTCGCCTACATGAGACAGTCTGTCTGCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 759) CCTACGGGAGGCATCAGGCAGATCTCGTCCGTGGTATAGCCGCACTCAAGTAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 760) CCTACGGGAGGCATCAGGCAGATCTCGTCTACGGCACGTTGTGGAAACTCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 761) CCTACGGGAGGCATCAGGCAGATCTCGATGCTGCAACACTTAGGCAGGTTCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 762) CCTACGGGAGGCATCAGGCAGATCTCGTTCTCATGGAGGTAAGACTACTGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 763) CCTACGGGAGGCATCAGGCAGATCTCGCATAGTGATTGGCGCGAAGTTTCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 764) CCTACGGGAGGCATCAGGCAGATCTCGGCTATCAAGACACGATACACTGCCAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 765) CCTACGGGAGGCATCAGGCAGATCTCGCCGTGACAACTCTTGAAATCCCGGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 766) CCTACGGGAGGCATCAGGCAGATCTCGCGTTCCTTGTTAGTTAGGGAGCGAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 767) CCTACGGGAGGCATCAGGCAGATCTCGGGAATTATCGGTTTACTGTGGCCGAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC (SEQ ID NO: 768) CCTACGGGAGGCATCAGGCAGATCTCGCATCAAGCATAGATATAAGGCCCAAGTCAGTCAGCCGGATTAGATACCCTAGTAGTC

In another embodiment, spike-in control compositions are provided for use in a method that simultaneously 1) controls for cross-contamination and/or sample swapping and 2) control for different GC content samples (e.g., low, balanced, and high GC content). In this embodiment, nucleic acid constructs are used with barcode sequence fragments and primer binding site fragments, and with GC content fragments where the barcode sequence fragments and the GC content fragments are optionally positioned between universal sequence fragments (see FIG. 4 ). In one embodiment, the barcode sequence fragment is linked at its 3′ end to the 5′ end of the GC content fragment, and the barcode sequence fragment is linked at its 5′ end to a universal sequence fragment while the GC content fragment is linked at its 3′ end to a universal sequence fragment. Further in this embodiment, primer binding site fragments flank the universal sequence fragments. In this embodiment, the GC content fragment can be used to control for polymerase GC content bias.

In this embodiment, the different GC content fragments (e.g., low, balanced, and high GC content) have the same barcode sequence fragments at each GC percentage (e.g., low, balanced, and high GC content), but for each separate sample the barcode sequence fragments are different (see FIG. 4 ).

In this embodiment, the GC content fragment can be from about 100 base pairs in length to about 270 base pairs in length, from about 100 base pairs in length to about 260 base pairs in length, from about 100 base pairs in length to about 250 base pairs in length, from about 100 base pairs in length to about 240 base pairs in length, from about 100 base pairs in length to about 230 base pairs in length, from about 100 base pairs in length to about 220 base pairs in length, from about 100 base pairs in length to about 210 base pairs in length, from about 100 base pairs in length to about 200 base pairs in length, from about 100 base pairs in length to about 190 base pairs in length, from about 100 base pairs in length to about 180 base pairs in length, from about 100 base pairs in length to about 170 base pairs in length, from about 100 base pairs in length to about 160 base pairs in length, from about 100 base pairs in length to about 150 base pairs in length, from about 100 base pairs in length to about 140 base pairs in length, from about 100 base pairs in length to about 130 base pairs in length, from about 100 base pairs in length to about 120 base pairs in length, from about 50 base pairs in length to about 270 base pairs in length, from about 50 base pairs in length to about 260 base pairs in length, from about 50 base pairs in length to about 250 base pairs in length, from about 50 base pairs in length to about 240 base pairs in length, from about 50 base pairs in length to about 230 base pairs in length, from about 50 base pairs in length to about 220 base pairs in length, from about 50 base pairs in length to about 210 base pairs in length, from about 50 base pairs in length to about 200 base pairs in length, from about 50 base pairs in length to about 190 base pairs in length, from about 50 base pairs in length to about 180 base pairs in length, from about 50 base pairs in length to about 170 base pairs in length, from about 50 base pairs in length to about 160 base pairs in length, from about 50 base pairs in length to about 150 base pairs in length, from about 50 base pairs in length to about 140 base pairs in length, from about 50 base pairs in length to about 130 base pairs in length, from about 50 base pairs in length to about 120 base pairs in length, from about 60 base pairs in length to about 120 base pairs in length, from about 70 base pairs in length to about 120 base pairs in length, from about 80 base pairs in length to about 120 base pairs in length, from about 90 base pairs in length to about 120 base pairs in length, or from about 100 base pairs in length to about 120 base pairs in length.

In embodiments where GC content fragments are present, the GC content of the GC content fragments can vary. As exemplary embodiments, the GC content fragments can have GC contents of about 1 to about 40 percent, about 1 to about 35 percent, about 1 to about 30 percent, about 1 to about 25 percent, about 1 to about 20 percent, about 35 to about 65 percent, about 40 to about 65 percent, about 40 to about 60 percent, about 40 to about 55 percent, about 40 to about 50 percent, about 45 to about 65 percent, about 45 to about 60 percent, about 45 to about 55 percent, about 45 to about 50 percent, about 65 to about 100 percent, about 65 to about 95 percent, about 65 to about 90 percent, about 65 to about 85 percent, about 65 to about 80 percent, about 65 to about 75 percent, about 65 to about 70 percent, about 60 to about 100 percent, about 60 to about 95 percent, about 60 to about 90 percent, about 60 to about 85 percent, about 60 to about 80 percent, about 60 to about 75 percent, or about 60 to about 70 percent. In one aspect, the GC content fragments can have low (e.g., about 1 to about 40 percent), balanced (e.g., about 40 to about 60 percent or about 45 to about 60 percent), or high GC content (e.g., about 60 to about 100 percent or about 65 to about 100 percent). In this embodiment, the GC content fragments in different nucleic acid constructs can have, for example, at least one, two, three, or four different GC content percentages in the different nucleic acid constructs (see FIG. 4 ).

The nucleic acid construct further comprises at least a first and a second primer binding site fragment. In this aspect, the primers can be any primers of interest. In this embodiment, the first primer binding site fragment can be linked at its 3′-end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment can be linked at its 5′ end to the 3′ end of the second universal sequence fragment. In another embodiment, the universal sequence fragments are lacking and the primer binding site fragments are linked to the 5′ and 3′ ends of the barcode sequence fragment. In various embodiments, the primer binding site fragments can range in length from about 15 base pairs to about 28 base pairs, from about 15 base pairs to about 26 base pairs, from about 15 base pairs to about 24 base pairs, from about 15 base pairs to about 22 base pairs, from about 15 base pairs to about 20 base pairs, from about 16 base pairs to about 22 base pairs, from about 16 base pairs to about 20 base pairs, from about 17 base pairs to about 20 base pairs, or can be about 18 base pairs.

In an illustrative embodiment, the nucleic acid construct is a deoxyribonucleic acid construct. In another aspect, the nucleic acid construct is a ribonucleic acid. In another embodiment, the nucleic acid construct is incorporated into a plasmid. In yet another embodiment, the nucleic acid construct is incorporated into the genome of an organism.

In all of the various embodiments described above, the entire nucleic acid construct, not including plasmid sequence if a plasmid is present, can range in length from about 80 base pairs to about 300 base pairs, from about 80 base pairs to about 290 base pairs, from about 80 base pairs to about 280 base pairs, from about 80 base pairs to about 270 base pairs, from about 80 base pairs to about 260 base pairs, from about 80 base pairs to about 250 base pairs, from about 80 base pairs to about 240 base pairs, from about 80 base pairs to about 230 base pairs, from about 80 base pairs to about 220 base pairs, from about 80 base pairs to about 210 base pairs, from about 80 base pairs to about 200 base pairs, from about 80 base pairs to about 190 base pairs, from about 80 base pairs to about 180 base pairs, from about 80 base pairs to about 170 base pairs, or from about 80 base pairs to about 160 base pairs.

In another embodiment, any of the nucleic acids constructs, incorporated into a plasmid or not incorporated or encapsulated or not encapsulated, can be in the form of a kit for qPCR. In this illustrative aspect, the kit can further comprise a reagent for nucleic acid extraction, a reagent for nucleic acid purification, a reagent for amplification (for example a polymerase), a probe (e.g., a TaqMan probe), and/or instructions for use of the kit. In this illustrative embodiment, the kit can comprise more than one of the qPCR control compositions wherein each control composition comprises a different nucleic acid construct wherein the different nucleic acid constructs comprise different barcode sequence fragments (e.g., see the barcode sequence fragments contained in SEQ ID NOS:1 to 384 or SEQ ID NOS:384 to 768).

In yet another illustrative aspect, the kits described herein can comprise more than one of any of the control compositions described herein wherein the nucleic acid construct in each control composition is encapsulated in a different type of liposome. In this embodiment, each control composition wherein the nucleic acid construct is encapsulated in a different type of liposome may have a different barcode sequence fragment to differentiate the various types of liposomes (see FIGS. 5 and 6 ).

In one aspect, quantitative PCR (qPCR) is performed on a target nucleic acid in a sample to quantify the target nucleic acid, and the control compositions described herein are used to control for cross-contamination, sample swapping, and/or for GC content bias in the qPCR assay. Methods and devices for performing qPCR are well-known in the art. To distinguish between the target nucleic acid and the nucleic acid constructs, described herein for use as control compositions, unique probes can be used that are complementary to and that hybridize to either the target nucleic acid or the nucleic acid constructs described herein and which are linked to different fluorophores. In one embodiment, the probe can hybridize to the barcode sequence fragment portion of the nucleic acid construct described herein. In another embodiment, where different GC content fragments with different percent GC content are used, the probe can hybridize to the barcode sequence fragment in combination with sequences of the specific GC content fragment being detected (see FIG. 4 ). In this embodiment, probes specific to a particular GC content fragment can be labeled with different fluorophores so that the different GC content fragments can be distinguished during qPCR (see FIG. 4 ). Similarly, in encapsulation embodiments where nucleic acid constructs in different types of liposomes, for example, are being distinguished, probes directed to the unique barcode sequence fragment in each encapsulated nucleic acid construct, and with different fluorophores attached to the probe can be used to distinguish nucleic acid constructs within liposomes of different compositions (see FIG. 5 ).

The probes can be any type of probe suitable for use in a qPCR assay and suitable for distinguishing between the various nucleic acid constructs, encapsulated or not encapsulated, described herein, and for allowing for quantitation of the target nucleic acid. An exemplary probe for use in the methods and compositions described herein is a hydrolysis probe (e.g. a TacMan probe). In exemplary embodiments, the probes can be labeled with fluorescent compounds, or other labeling agents known to those of skill in the art, that allow for detection and/or quantification of amplified DNA, such as by qPCR. In illustrative embodiments, the labels on the probes can be selected from 6-carboxyfluorescein (FAM™), TET™ (tetrachloro-6-carboxyfluorescein), JOE™ (2,7, -dimethoxy-4,5-dichloro-6-carboxyfluorescein), VIC™, HEX (hexachloro-6-carboxyfluorescein), TAMRA™ (6-carboxy-N,N,N′,N′-tetramethylrhodamine), BHQ™, SYBR® Green, Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, ROX, and/or Texas Red.

In one embodiment, the probes, primers for use in qPCR, and the nucleic acid constructs, including nucleic acid constructs incorporated into a plasmid, described herein can be made by methods well-known in the art, including chemical syntheses and recombinant methods. Such techniques are described in Sambrook et al., “Molecular Cloning: A Laboratory Manual”, 3rd Edition, Cold Spring Harbor Laboratory Press, (2001), incorporated herein by reference. Plasmids, primers, probes, and the nucleic acid constructs described herein can also be made commercially (e.g., Blue Heron, Bothell, Wash. 98021). Techniques for purifying or isolating the probes, primers, or nucleic acid constructs, including nucleic acid constructs incorporated into a plasmid, described herein are well-known in the art. Such techniques are described in Sambrook et al., “Molecular Cloning: A Laboratory Manual”, 3rd Edition, Cold Spring Harbor Laboratory Press, (2001), incorporated herein by reference. The nucleic acid constructs, including nucleic acid constructs incorporated into a plasmid, described herein can be analyzed by techniques known in the art, such as sequencing, to determine if the sequence is correct.

In one illustrative aspect, the nucleic acid construct, incorporated into a plasmid or not incorporated into a plasmid, can be encapsulated. In one exemplary embodiment, the nucleic acid construct, incorporated into a plasmid or not incorporated into a plasmid, can be encapsulated in a liposome, and the liposome can comprise a lipid selected from the group consisting of cholesterol, a cholesterol ester salt, a lipopolysaccharide, a sphingolipid, a peptidoglycan, a phospholipid, any other suitable lipid, and combinations thereof.

In this embodiment, liposomes can be closed, spherical vesicles comprising amphiphilic lipids in proportions such that they arrange themselves into multiple concentric bilayers when hydrated in aqueous solutions. In another aspect, the liposomes can be converted into single bilayer liposomes which are useful carriers of both hydrophilic molecules, which can reside entrapped in the aqueous interior of the liposome, and of hydrophobic molecules, which can reside entrapped in the lipid bilayer. An exemplary hydrophilic chain constituent is polyethylene glycol.

In various embodiments, the lipids can include those having two hydrocarbon chains, typically acyl chains, and a polar head group, such as phospholipids and glycolipids. In this aspect, phospholipids may include any one type of phospholipid or a combination of phospholipids capable of forming liposomes, including, but not limited to, phosphatidylcholines, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, and sphingomyelin, where the two hydrocarbon chains are typically between about 14 to 22 carbons in length, and have varying degrees of unsaturation. The glycolipids include, but are not limited to, cerebrosides and gangliosides. Exemplary phosphatidylcholines, include those obtained from natural sources or those that are partially or wholly synthetic, or are of variable chain length and unsaturation.

In various embodiments, the nucleic acid construct can be encapsulated, incorporated into a plasmid or not incorporated into a plasmid, into a simulated cell membrane that mimics the cell membrane of the microorganism or a eukaryotic cell, or another cell of interest. In one illustrative embodiment, lipids with varying crystal transition temperatures, including cholesterol and lipopolysaccharide, can be incorporated during encapsulation to better mimic the mechanical and material characteristics of a microorganism cell wall (e.g., a bacterial cell wall). In this embodiment, variation in liposome production parameters such as the lipid:DNA ratio, the solvent:non-solvent ratio, and the lipid charge can be used to better tune the liposome composition and size to mimic the cell membrane of the microorganism or a eukaryotic cell, or another cell of interest.

For example, membrane rigidity may be increased with increasing amounts of cholesterol. In one embodiment, this allows the production of a range of liposomes that include easy to lyse (i.e., non-resistant liposomes) through difficult to lyse liposomes (i.e., resistant liposomes). In another embodiment, LPS may be used to mimic Gram-negative bacterial membranes. The hydrated saccharide chains can act as a barrier to hydrophobic species while the phospholipid layer can act as a barrier to hydrophilic species. A periplasm layer of water and peptidoglycan (PG) separates the LPS outer membrane from an inner membrane composed of a more conventional phospholipid lipid bilayer. Polyethylene Glycol (PEG) is a hydrophilic, biologically inert, synthetic material that may confer similar membrane robustness. The PEG can assemble into a brush-like layer on the outer membrane of the liposomes, and act as a hydrated barrier while also increasing the apparent size. Although PEG has been extensively used in liposomes for drug delivery, it may not have been demonstrated as an LPS mimic in an artificial cell. PG, teichoic acids, or similar materials can be added to mimic a Gram-positive cell wall, as the thick PG layers increase lysis resistance. In one aspect, after synthesis, liposome size can be adjusted by extruding the liposomes through a filter membrane with well-defined pore sizes. In this embodiment, the final liposome will comprise small, unilamellar vesicles with a size that is determined by the pore size in the membrane used for extrusion. With no extrusion step, the liposomes may be larger, multi-lamellar liposomes. In one illustrative aspect, direct encapsulation of the nucleic acid construct without a plasmid or genome backbone is used (shown schematically in FIGS. 5 and 6 ).

In all of the encapsulation embodiments described above, encapsulation of the control composition for qPCR, including the nucleic acid construct, or by incorporation into the genome of a cell (e.g., a bacterial or eukaryotic cell) allows for the control composition for qPCR to be used in every step of qPCR for an unknown test sample: from nucleic acid extraction to nucleic acid purification to qPCR because degradation of the control sample can be avoided so that sample cross-contamination and sample swapping can be effectively monitored throughout the protocol. In another aspect, the nucleic acid constructs can be encapsulated in a simulated cell membrane to control for differential lysis during sample preparation of different samples. In another illustrative aspect, encapsulation of the nucleic acid constructs described herein can enable control for extraction efficiency, cross contamination, and extraction quality.

In embodiments where the nucleic acid construct is not artificially encapsulated in, for example, a liposome, the nucleic acid construct, or a barcode sequence fragment, can be incorporated into the genome of a microorganism for use as a control composition for qPCR. These embodiments are shown schematically in FIGS. 2A, 2B, and 2C. If the primer binding sites are present in the microorganism to be utilized, the microorganism could be modified utilizing gene editing, for example, so that the natural primer binding sites are removed (see FIG. 2B). In another embodiment, the natural sequence between natural primer binding sites in the microorganism could be replaced with a barcode sequence (see FIG. 2C). In one aspect, the CRISPR/Cas9 system for genome editing could be used as well as other genome editing systems, such as ZFNs, custom designed homing endonucleases, and TALENS systems.

The CRISPR/Cas9 system for genome editing has benefits over other genome editing systems. In this embodiment, the Cas9 endonuclease is capable of introducing a double strand break into a DNA target sequence (e.g., the natural primer binding sites described above). In this aspect, the Cas9 endonuclease is guided by the guide polynucleotide (e.g., guide RNA) to recognize and optionally introduce a double strand break at a specific target site into the genome of a cell, such as a microorganism, a eukaryotic cell, or another cell of interest for use in the methods described herein. The Cas9 endonuclease can unwind the DNA duplex in close proximity to the genomic target site and cleaves both DNA strands upon recognition of a target sequence by a guide polynucleotide (e.g., guide RNA), but only if the correct protospacer-adjacent motif (PAM) is approximately oriented at the 3′ end of the target. In this embodiment, the donor polynucleotide construct (e.g., the nucleic acid construct described herein) can then be incorporated into the genomic target site. Methods for using the CRISPR/Cas9 system for genome editing are well-known in the art.

In one illustrative aspect, for qPCR, the nucleic acids in the sample (e.g., microorganisms such as bacteria or viruses) and the nucleic acids in the control composition for qPCR (e.g., the nucleic acid construct incorporated or not incorporated into a plasmid or into the genome of a microorganism), are extracted and purified for analysis. In various embodiments, the preparation of the nucleic acids (e.g., DNA or RNA) can involve rupturing the cells that contain the nucleic acids (e.g., cells of a microorganism or the nucleic acid construct in a simulated cell membrane) and isolating and purifying the nucleic acids (e.g., DNA or RNA) from the lysate. Techniques for rupturing cells and for isolation and purification of nucleic acids (e.g., DNA or RNA) are well-known in the art. In one embodiment, for example, nucleic acids may be isolated and purified by rupturing cells using a detergent or a solvent, such as phenol-chloroform. In another aspect, nucleic acids (e.g., DNA or RNA) may be separated from the lysate by physical methods including, but not limited to, centrifugation, pressure techniques, or by using a substance with an affinity for nucleic acids (e.g., DNA or RNA), such as, for example, beads that bind nucleic acids. In one embodiment, after sufficient washing, the isolated, purified nucleic acids may be suspended in either water or a buffer. In another aspect, the nucleic acids (e.g., DNA or RNA) are “isolated” or “purified” before qPCR. In one embodiment, “isolated” means that the nucleic acids used in qPCR are removed from their normal environment (e.g., a nucleic acid is removed from the genome of an organism). In another aspect, “purified” means in the context of the nucleic acids that are used in qPCR that the nucleic acids are substantially free of other cellular material, or culture medium, or other chemicals used in the extraction process. In other embodiments, commercial kits are available, such as Qiagen™ (e.g., Qiagen DNeasy PowerSoil Kit™), Nuclisensm™, and Wizard™ (Promega), and Promegam™ for extraction and purification of nucleic acids. Methods for preparing nucleic acids for qPCR are also described in Green and Sambrook, “Molecular Cloning: A Laboratory Manual”, 4th Edition, Cold Spring Harbor Laboratory Press, (2012), incorporated herein by reference.

In various illustrative embodiments, using the control compositions for qPCR described herein, patient samples or environmental samples (e.g., containing animal, plant, bacteria, viruses, fungi, or archaea) can be analyzed by qPCR. In accordance with the invention, the term “patient” means a human or an animal, such as a domestic animal (e.g., a dog or a cat). Accordingly, the methods and control compositions for qPCR described herein can be used, for example, for human clinical medicine (e.g., infectious disease diagnosis, cancer diagnosis, infectious disease biosurveillance), veterinary applications, forensics, environmental or ecological use.

In various aspects, the patient can be a human, or in the case of veterinary applications, can be a laboratory, agricultural, domestic or wild animal. In one embodiment, the patient can include, but is not limited to, a human, a laboratory animal such as a rodent (e.g., mice, rats, hamsters, etc.), a rabbit, a monkey, a chimpanzee, a domestic animal such as a dog, a cat, and a rabbit, and an agricultural animal such as a cow, a horse, a pig, a sheep, a goat, a chicken, and a wild animal in captivity such as a bear, a panda, a lion, a tiger, a leopard, an elephant, a zebra, a giraffe, a gorilla, a dolphin, and a whale.

In various illustrative embodiments, the samples that can be tested using the control compositions for qPCR and the methods described herein comprise patient body fluids including, but not limited to, urine, nasal secretions, nasal washes, inner ear fluids, bronchial lavages, bronchial washes, alveolar lavages, spinal fluid, bone marrow aspirates, sputum, pleural fluids, synovial fluids, pericardial fluids, peritoneal fluids, saliva, tears, gastric secretions, a stool sample, reproductive tract secretions, such as seminal fluid, lymph fluid, and whole blood, serum, or plasma, or any other suitable patient sample. In another embodiment, nucleic acids extracted from microorganisms (e.g., bacteria or viruses) isolated or purified from patient samples or environmental samples can be tested using the control compositions for qPCR and methods described herein. In various embodiments, patient tissue samples that can be tested by using the control compositions for qPCR and the methods described herein can include tissue biopsies of hospital patients or out-patients and autopsy specimens. As used herein, the term “tissue” includes, but is not limited to, biopsies (including tumor biopsies), autopsy specimens, cell extracts, hair, tissue sections, aspirates, tissue swabs, and fine needle aspirates.

In various illustrative embodiments, environmental samples that can be tested by using the control compositions for qPCR and the methods described herein can be selected from the group consisting of a soil sample, a water sample, a food sample, an air sample, a plant sample, an industrial waste sample, an agricultural sample, a surface wipe sample, a dust sample, a hair sample, and an animal sample, or any other suitable environmental sample.

In various illustrative embodiments, the microorganisms present in the patient sample or the environmental sample to be tested can be bacteria or viruses. In this aspect, the bacteria can be selected from Gram-negative and Gram-positive cocci and bacilli, acid-fast bacteria, and can comprise antibiotic-resistant bacteria, or any other known bacteria having a nucleic acid sequence to target. In another illustrative aspect, the bacteria can be selected from the group consisting of Pseudomonas species, Staphylococcus species, Streptococcus species, Escherichia species, Haemophillus species, Neisseria species, Chlamydia species, Helicobacter species, Campylobacter species, Salmonella species, Shigella species, Clostridium species, Treponema species, Ureaplasma species, Listeria species, Legionella species, Mycoplasma species, and Mycobacterium species, or the group consisting of S. aureus, P. aeruginosa, and E. coli. In another aspect, the viruses can be selected from DNA and RNA viruses, or can be selected from the group consisting of papilloma viruses, parvoviruses, adenoviruses, herpesviruses, vaccinia viruses, arenaviruses, coronaviruses, rhinoviruses, respiratory syncytial viruses, influenza viruses, picornaviruses, paramyxoviruses, reoviruses, retroviruses, and rhabdoviruses. In another illustrative embodiment, mixtures of any of these microorganisms can be present in the patient sample or the environmental sample. In yet another embodiment, the sample to be tested comprises eukaryotic cells.

In one illustrative aspect, a method is provided. The method is for monitoring cross-contamination or sample swapping over all steps of qPCR including collection of a sample comprising DNA, DNA extraction from the sample, purification of the extracted DNA, and qPCR. The method comprises a) spiking the sample with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment linked to primer binding site fragments and wherein the nucleic acid construct is a deoxyribonucleic acid construct, b) extracting total DNA wherein total DNA comprises the DNA from the sample and DNA from the nucleic acid construct, c) purifying total DNA, d) performing qPCR on the extracted, purified total DNA, and e) detecting the nucleic acid construct in total DNA using a probe.

In another illustrative aspect, a method is provided. The method is for monitoring cross-contamination or sample swapping during qPCR. The method comprises a) spiking the sample, after DNA extraction and purification and before qPCR, with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment, and 5′ and 3′ primer binding site fragments, wherein the nucleic acid construct is a deoxyribonucleic acid construct, wherein total DNA is obtained after spiking the sample, and wherein total DNA comprises the DNA from the sample and the DNA from the nucleic acid construct, b) extracting total DNA wherein total DNA comprises the DNA from the sample and DNA from the nucleic acid construct, c) purifying total DNA, d) performing qPCR on the extracted, purified total DNA, and e) detecting the nucleic acid construct in total DNA using a probe.

In another embodiment, a method is provided for qPCR using any of the control compositions described herein that contain GC content fragments, where the method is for monitoring sample cross-contamination and/or sample swapping and for controlling GC content bias. The method comprises a) extracting DNA from a sample, b) purifying the DNA, c) spiking the sample, after DNA extraction and purification and before qPCR, with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment, at least one GC content fragment, and 5′ and 3′ primer binding site fragments, wherein the nucleic acid construct is a deoxyribonucleic acid construct, wherein total DNA is obtained after spiking the sample, and wherein total DNA comprises the DNA from the sample and the DNA from the nucleic acid construct, d) performing qPCR on the extracted, purified total DNA, and e) detecting the nucleic acid construct in total DNA using a probe.

In another embodiment, a method is provided for qPCR using any of the control compositions described herein that contain GC content fragments. The qPCR method is for monitoring sample cross-contamination and/or sample swapping and for controlling GC content bias in samples. The method comprises a) spiking a sample with a qPCR control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment, at least one GC content fragment, and 5′ and 3′ primer binding site fragments, and wherein the nucleic acid construct is a deoxyribonucleic acid construct, b) extracting total DNA from the sample wherein total DNA comprises the DNA from the sample and the DNA from the nucleic acid construct, c) purifying total DNA, d) performing qPCR on the extracted, purified total DNA, and e) detecting and the nucleic acid construct in total DNA using a probe. 

What is claimed is:
 1. A method for monitoring cross-contamination or sample swapping over one or more steps of a qPCR protocol including collection of a sample comprising DNA, DNA extraction from the sample, purification of the extracted DNA, and qPCR, the method comprising, a) spiking the sample with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment, wherein the nucleic acid construct is a deoxyribonucleic acid construct, and wherein the nucleic acid construct further comprises at least a first and a second primer binding site fragment; b) extracting total DNA wherein total DNA comprises the DNA from the sample and DNA from the nucleic acid construct; c) purifying total DNA; d) performing qPCR on the extracted, purified total DNA; and e) detecting the nucleic acid construct in total DNA using a probe.
 2. The method of claim 1 wherein the method is used to determine if cross-contamination between samples has occurred or if sample swapping has occurred.
 3. The method of claim 1 wherein the nucleic acid construct further comprises at least a first and a second universal sequence fragment and wherein the first universal sequence fragment is linked to the 5′ end of the barcode sequence fragment and the second universal sequence fragment is linked to the 3′ end of the barcode sequence fragment.
 4. The method of claim 3 wherein the first primer binding site fragment is linked at its 3′ end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of the second universal sequence fragment.
 5. The method of claim 1 wherein the barcode sequence fragment comprises a unique sequence not present in any known genome.
 6. A method for monitoring sample cross-contamination and/or sample swapping of nucleic acids during qPCR, the method comprising, a) extracting DNA from a sample; b) purifying the DNA; c) spiking the sample, after DNA extraction and purification and before qPCR, with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment and at least a first and a second primer binding site fragment, and at least one GC content fragment, and wherein the nucleic acid construct is a deoxyribonucleic acid construct, wherein total DNA is obtained after spiking the sample, and wherein total DNA comprises the DNA from the sample and the DNA from the nucleic acid construct; d) performing qPCR on the extracted, purified total DNA; and e) detecting the nucleic acid construct in total DNA using a probe.
 7. A method for monitoring sample cross-contamination and/or sample swapping of nucleic acids during qPCR, the method comprising, a) spiking a sample with a control composition comprising a nucleic acid construct wherein the nucleic acid construct comprises at least one barcode sequence fragment and at least a first and a second primer binding site fragment, and at least one GC content fragment and wherein the nucleic acid construct is a deoxyribonucleic acid construct; b) extracting total DNA from the sample wherein total DNA comprises the DNA from the sample and the DNA from the nucleic acid construct; c) purifying total DNA; d) performing qPCR on the extracted, purified total DNA; and e) detecting the nucleic acid construct in total DNA using a probe.
 8. The method of claim 6 wherein sample cross-contamination and/or sample swapping can be monitored over all steps of a qPCR protocol including collection of the sample, extraction of total DNA, purification of the extracted total DNA, and qPCR.
 9. The method of claim 7 wherein sample cross-contamination and/or sample swapping can be monitored over all steps of a qPCR protocol including collection of the sample, extraction of total DNA, purification of the extracted total DNA, and qPCR.
 10. The method of claim 6 wherein the barcode sequence fragment comprises a unique sequence not present in any known genome, wherein the nucleic acid construct further comprises at least a first and a second universal sequence fragment wherein the first universal sequence fragment is linked to the 5′ end of the barcode sequence fragment, the barcode sequence fragment is between the first universal sequence fragment and the GC content fragment, and the second universal sequence fragment is linked to the 3′ end of the GC content fragment, and wherein the first primer binding site fragment is linked at its 3′ end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of the second universal sequence fragment.
 11. The method of claim 7 wherein the barcode sequence fragment comprises a unique sequence not present in any known genome, wherein the nucleic acid construct further comprises at least a first and a second universal sequence fragment wherein the first universal sequence fragment is linked to the 5′ end of the barcode sequence fragment, the barcode sequence fragment is between the first universal sequence fragment and the GC content fragment, and the second universal sequence fragment is linked to the 3′ end of the GC content fragment, and wherein the first primer binding site fragment is linked at its 3′ end to the 5′ end of the first universal sequence fragment and the second primer binding site fragment is linked at its 5′ end to the 3′ end of the second universal sequence fragment. 